Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?

Joyce C. McCann[1] and Bruce N. Ames[1]

Nutrition and Metabolism Center, Children's Hospital Oakland Research Institute, Oakland, California, USA

ABSTRACT Vitamin D insufficiency is common in the United States; the elderly and African-Americans are at particularly high risk of deficiency. This review, written for a broad scientific readership, presents a critical overview of scientific evidence relevant to a possible causal relationship between vitamin D deficiency and adverse cognitive or behavioral effects. Topics discussed are *1*) biological functions of vitamin D relevant to cognition and behavior; *2*) studies in humans and rodents that directly examine effects of vitamin D inadequacy on cognition or behavior; and *3*) immunomodulatory activity of vitamin D relative to the proinflammatory cytokine theory of cognitive/behavioral dysfunction. We conclude there is ample biological evidence to suggest an important role for vitamin D in brain development and function. However, direct effects of vitamin D inadequacy on cognition/behavior in human or rodent systems appear to be subtle, and in our opinion, the current experimental evidence base does not yet fully satisfy causal criteria. Possible explanations for the apparent inconsistency between results of biological and cognitive/behavioral experiments, as well as suggested areas for further research are discussed. Despite residual uncertainty, recommendations for vitamin D supplementation of at-risk groups, including nursing infants, the elderly, and African-Americans appear warranted to ensure adequacy. McCann, J. C., Ames, B. N. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? *FASEB J.* 22, 982–1001 (2008)

Key Words: calcitriol · cognition · depression · memory · brain development · cytokine theory

A LARGE BODY OF RESEARCH suggests that an inadequate dietary supply of any of a number of essential micronutrients (some 40 vitamins, minerals, and other small molecule essential nutrients) can adversely affect brain function (*e.g.*, refs. 1–4). Some studies also suggest positive effects of multivitamin and mineral supplementation on cognitive function (*e.g.*, refs. 5, 6). A causal relationship between micronutrient deficiencies and suboptimal brain function would have major public health implications. Large segments of the world (including the U.S.) population, particularly the poor, are known to be undernourished for a number of

micronutrients (7–9). A major effort to address micronutrient undernutrition as an adjunct to the various programs under way to improve dietary habits, particularly of the poor, would be well justified. One of us has discussed such an approach as a relatively inexpensive and efficacious adjunct to current public health programs (10–12).

This review is part of a series intended to provide critical summaries for a broad scientific readership of expert opinion and the available experimental evidence pertinent to whether there are causal linkages between individual micronutrient deficiencies and brain function. Recently, we reviewed evidence relevant to whether a causal relationship exists between cognitive dysfunction and availability during development of the omega-3 fatty acid docosahexaenoic acid (DHA) (2), choline (3), and iron (4).

It has been only some 25 years since the first reports suggesting that functions of vitamin D extended well beyond its classical role in systemic calcium homeostasis (13). Here, we provide a brief overview of recent mechanistic and direct evidence relevant to whether vitamin D is linked to cognitive or behavioral function. We also discuss the proinflammatory cytokine theory of cognitive/behavioral dysfunction relative to the immunomodulatory activity of vitamin D. Included is a critical summary of rodent studies that have examined cognitive/behavioral performance in mice lacking a functional vitamin D receptor, or in animals that have been restricted for UV light and dietary vitamin D.

Primary resources were recent research reports not yet reviewed, key earlier studies, and a large number of expert reviews and commentaries. We searched the literature by using a combination of techniques, including key word and author searches of the National Library of Medicine's PubMed database and the Science Citation Index Cited References database. We also surveyed citations included in recent research and review articles. Abstracts were not included. Because of the broad subject matter of this review and the fact that some subjects discussed are very active areas of re-

search, references cited are selective, with preference given to the most recent representative references in order to keep the bibliography of a manageable length.

BACKGROUND

The term "vitamin D" refers to either vitamin D2 (ergocalciferol) or D3 (cholecalciferol). A major source of vitamin D3 is fortified foods such as milk and some cereals. Vitamin D3 is naturally present in few foods, primarily fatty fish such as salmon, mackerel, and sardines, whereas some vitamin D2 is found in yeast and plants (14). Vitamin D2 is less active than vitamin D3 (15). The major source of vitamin D3 for most people is the action of UV radiation from the sun on a chemical in the skin related to cholesterol (7-dehydro-cholesterol) to form cholecalciferol, which is then enzymatically converted to 25-hydroxycholecalciferol ($25OHD_3$, or calcidiol). $25OHD_3$ is a stable circulating form of vitamin D that is usually measured in serum to indicate vitamin D status. The primary active form of vitamin D is calcitriol (1α,25-dihydroxycholecalciferol), which is formed from $25OHD_3$ by the mitochondrial enzyme 1,α-hydroxylase (CYP27B1). Throughout this review, we use the terms "calcitriol" and "25OHD3" to refer to the active form of vitamin D and its immediate biosynthetic precursor, respectively. The final activation step of calcitriol takes place in the kidney and in many other tissues throughout the body, as well as in white blood cells. (Vitamin D2 is also converted to a dihydroxy active form.) Calcitriol synthesized in the kidney is released into the bloodstream as a hormone, and circulates bound to a vitamin D-binding protein. Calcitriol is also synthesized in or adjacent to regulated cellular targets, thus acting in an autocrine and para-crine fashion as well. Calcitriol binds to the vitamin D receptor (VDR), which, in turn, binds to a vitamin D response element (VDRE) in the promoter region of regulated genes. Many calcitriol target genes have been identified (16–21). Calcitriol also binds to cell membrane receptors (22–24), initiating rapid nongenomic signaling, including rapid Ca^{2+} translocation through voltage-gated ion channels, and up-regulation of the mitogen-activated protein kinase (MAPK) cascade *via* a protein kinase C signaling pathway (25). A membrane receptor distinct from the VDR has been described (26, 27), but the VDR may also be involved (23, 28, 29).

The classical hormonal function of calcitriol is to control blood levels of calcium by regulating the expression of genes involved in its intestinal absorption, renal excretion, and movement in and out of bone. More recently, many other so-called noncalcemic functions of calcitriol have been identified, which include regulation of proliferative and apoptotic activity, immunomodulatory and prodifferentiation activity, and interaction with the rennin-angiotensin system (involved in the regulation of blood pressure), insulin secretion, and neuroprotective functions. These diverse functions are discussed in many general reviews; a few are cited here (13, 22, 23, 30–39). In this review, we will discuss a subset of these functions as they relate to the possible need for vitamin D for cognitive or behavioral function.

VITAMIN D STATUS, INSUFFICIENCY, AND DEFICIENCY

Vitamin D status is currently indicated by $25OHD_3$ concentration in serum (14). The National Academy of Sciences (NAS) used a cutoff value of 27.5 nmol/L (<11 ng/ml) $25OHD_3$ to indicate "vitamin D deficiency" for the purposes of setting Dietary Reference Intakes for vitamin D (14). The term "vitamin D insufficiency" represents the $25OHD_3$ concentration below which a subclinical deficiency is considered to exist; the cutoff value has generally been considered to correspond to the lower limit of the range of $25OHD_3$ in a normal population. The NAS cites several cutoff values determined from different populations, ranging from 37.5 nmol/L (15 ng/ml) to 77.5 nmol/L (31 ng/ml). Some experts have suggested that these cutoff values be raised (*e.g.*, refs. 40, 41). In this review, we use the general terms "low vitamin D" or "vitamin D inadequacy" to indicate either vitamin D insufficiency or deficiency. In discussing specific studies, we specify $25OHD_3$ concentrations when reported. Since calcitriol is synthesized and acts locally in a paracrine or autocrine fashion in the brain (as well as in many other tissues), it is likely that circulating concentrations of $25OHD_3$ will have a complex relationship to localized concentrations of calcitriol.

EXPERIMENTAL DESIGNS

The evidence to be discussed involves primarily three basic experimental designs. First, the supply of vitamin D or calcitriol were manipulated *in vitro* or *in vivo* by creating the conditions of vitamin D inadequacy through restricting exposure to UV radiation and limiting dietary intake or through increasing supply by supplementing the cell culture medium or treating subjects orally or by injection. Second, the functionality of calcitriol was restricted by using a mouse knockout strain (42) lacking a functional VDR (VDR-KO) (43). And third, experimental or population groups were examined for associations between blood concentrations of 25OHD3 and behavioral or biochemical endpoints.

RELEVANCE OF THE EXPERIMENTAL DATABASE TO HUMANS

The majority of evidence concerning the biology and mechanisms of action of vitamin D in the brain and most of the direct evidence for effects of vitamin D inadequacy on cognitive or behavioral function rely on experiments conducted in laboratory rats or mice. The

rodent strains used were all derived from species (*Rattus norvegicus* and *Mus musculus*) (44), known to be largely, though not exclusively, nocturnal (45). They are thus expected to be less exposed to sunlight than humans. It is unclear how this difference between rodents and humans might be reflected in differences in vitamin D biology or in sensitivity to limited availability of vitamin D. On the one hand, there is a large body of evidence indicating that vitamin D plays a key role in many important biological processes in both the development and function of the rodent nervous system, as will be briefly summarized here. And, on the basis of the very few comparative studies of which we are aware, there is evidence to suggest some striking similarities between humans and rodents. For example, vitamin D is synthesized in the skin in both rats and humans (46, 47), the distribution of VDR in human and rat brains is very similar (48), apoptotic effects of calcitriol on brain glial cells appear to be similar whether cells are from humans or rats (49), and serum concentrations of vitamin D-binding protein are similar in laboratory rats and humans (50). On the other hand, all of calcitriol's effects in humans and rodents are not the same. For example, calcitriol stimulates the production of the antimicrobial peptide cathelicidin in humans, but not mice (51, 52). Also, it has recently been demonstrated that, in rats, lithocholic acid can substitute for vitamin D under conditions of deficiency (53). It is not known if this mechanism exists in humans. Throughout the review, we have attempted to take the possibility of significant species differences in vitamin D biology into account in presenting and discussing experimental results.

MECHANISTIC EVIDENCE THAT LINKS VITAMIN D TO BRAIN DEVELOPMENT AND FUNCTION

Below are brief summaries of immunohistochemical, biochemical, and molecular biological evidence that point to the involvement of calcitriol in brain development and function. Because of the enormous size of the relevant literature, several examples have been selected for discussion, and references to more detailed treatment of specific topics are provided. The sections below point to: the ubiquitous presence of VDR and 1,α-hydroxylase (the terminal rate-limiting enzyme in the synthesis of calcitriol) in the brain; examples illustrating the involvement of calcitriol and its target gene products in neuronal differentiation and brain function; and the involvement of calcitriol-mediated membrane processes in brain function.

VDR and 1,α-hydroxylase, the terminal calcitriol-activating enzyme, are distributed throughout both the fetal and adult brain

VDR have been identified in more than 50 tissues (54). VDR and 1,α-hydroxylase (55) are distributed through-out the human adult brain (48, 56) and the rodent adult (57–61) and fetal (62–64) brain. The distribution of VDR in human and rodent brains is very similar (48). VDR have been reported in the nuclei of a number of cell types in the central nervous system (CNS), including microglia, astrocytes, oligodendrocytes (the cells that make myelin), and Schwann cells, their counterpart in the peripheral nervous system (60, 65–67). VDR have been detected in the rat fetal brain at all times examined (as early as ED12) (62, 64), increasing in number until birth (64). Calcitriol can cross the blood-brain barrier (68), but it is also synthesized in the brain (48). Calcitriol injected into hamster brains was found strongly concentrated in the nuclei of neurons in several brain regions involved in memory and cognition (59).

Vitamin D target genes in the brain

As indicated above, the expression of many genes has been shown to be affected by calcitriol treatment, but only a relatively small number of studies have investigated target genes in brain tissues or cells. Specific gene products whose expression in the brain or brain cells has been shown to be altered by calcitriol treatment are summarized in **Table 1** (57, 68–81). Recently, effects on expression of multiple genes and proteins in brain tissue from offspring restricted for dietary vitamin D and UV radiation during fetal development were reported (21, 82). These are the first studies of which we are aware that examined effects of vitamin D deficiency on gene or protein expression. For general discussion of calcitriol target genes, see several reviews (30, 36–38, 83, 84).

Several gene products that have specific relevance to cognitive or behavioral function are discussed further below.

Neurotrophins (NGF, NT-3, NT4/5) and the neurotrophic factor GDNF

Neurotrophins are secreted proteins that support the survival and differentiation of neurons (85, 86) and also function in the adult brain. Of the 4 neurotrophins in mammals (NGF, BDNF, NT-3, and NT4/5), calcitriol affects the expression of 3 of them, as indicated above. NGF is present mainly in the hippocampus and neocortex, where it affects neurotransmission and synaptic plasticity (85). Functions of the other neurotrophins linked to calcitriol include enhancement of synaptic transmission in the hippocampus by NT-3 (87), and involvement in calcium signaling by NT4/5 (88).

GDNF (73, 89) is another type of neurotrophic factor. It is a distant member of the transforming growth factor β (TGFβ) superfamily. GDNF is expressed in neural and non-neural tissues (85). In the brain, GDNF affects the survival and differentiation of dopaminergic cells (90, 91) and is present at relatively high levels in the developing striatum of the rat (91).

TABLE 1. *Calcitriol target genes in the brain*

Gene products whose expression in the brain or brain cells has been reported to be affected by calcitriol
Neurotrophins and other growth factors
NGF (69–71), NT-3 and NT-4/5 (72), GDNF (73, 74), TGF-β_2 (75)
Calcium-binding proteins
Calbindin D28K, parvalbumin, calretinin (76, 111)
Protein subunits for L-TYPE VOLTAGE-SENSITIVE CA^{2+} channels (L-TYPE VSCCs) (141, 148)
Transcription factors or enzymes involved in signal transduction pathways
N-myc, c-myc, protein kinase C family (PKC) (75)
Other enzymes
Choline acetyltransferase, responsible for synthesis of the neurotransmitter acetylcholine (77)
γ-Glutamyltranspeptidase, involved in recyling of the reactive oxygen species scavenger glutathione (78)
Hormones
Oxytocin, the "trust hormone"[a]

Biochemical or cellular brain functions in which calcitriol target gene products are involved
Synaptogenesis (formation of synaptic connections)
Synaptic plasticity (*e.g.*, memory formation)
Calcium signaling and homeostasis
Neurotransmission and neurotransmitter synthesis
Survival and differentiation of dopaminergic and other neurons
Control of toxic free radicals

Behavior affected by target gene product dysfunction
Learning and memory
Motor control
Maternal or social behavior
Aging (neuronal density)

See text for additional references and discussion. [a]Recently, an *in silico* study identified the VDR DNA binding sequence in the oxytocin receptor gene (16). On the basis of the colocalization of the VDR receptor with oxytocin immunoreactivity in the rat hypothalamus, it was suggested that calcitriol may affect the expression of oxytocin (79). Oxtocin, termed the "trust hormone," is involved in a variety of physiological processes, including labor induction and the milk-eject reflex, as well as stimulating the feeling of trust (80).

Recent evidence indicates its probable involvement in synaptogenesis (92). In striatal neurons *in vitro*, GDNF treatment activated intracellular signaling involving the p42/p44 MAPK pathway and increased dendritic arborization of the neurotransmitter γ-aminobutryric acid (GABA)- and calbindin-positive neurons (93).

GDNF treatment rescued damaged dopamine neurons and associated functions in rodent and primate Parkinson's models (94–98), possibly by reducing oxidative stress (99). In the Parkinson's model in rats, calcitriol treatment also attenuated neurotoxicity (100, 101). Results of GDNF treatment in alleviating Parkinson's symptoms in human clinical trials have been mixed (102–106); treatment with calcitriol or calcitriol analogues has not been investigated. In a different rodent model of neurotoxicity, neuroprotective effects

were dose dependent and were elicited with calcitriol at the same concentrations that also increased GDNF levels (107).

Calcium-binding proteins

Many calcium-binding proteins are present throughout the body (108) and in the CNS (109, 110). As indicated above, three have been shown to be modulated by vitamin D in brain tissues or cells—calbindin-D28K, parvalbumin, and calretinin (76, 111). All three of these calcium-binding proteins are widely distributed in both the adult and fetal brain. In the adult brain, each of these proteins is uniquely distributed, and they also exhibit temporal patterns during development (112–115) and aging (116). They fill the cytoplasm of neuronal processes, are commonly used as neuronal markers (117), and are present in some areas of the brain at very high concentrations. For example, calbindin-D28k comprises some 15% of the total protein in adult Purkinje cells in the cerebellum (110). All three proteins are believed to serve a neuroprotective role as calcium buffers (*e.g.*, ref. 118), but they are also involved in critical brain functions. Additional information on the functions of parvalbumin and calretinin in the brain can be found in refs. 109 and 119.

In addition to its calcium-buffering properties, calbindin-D28k undergoes a conformational change on binding Ca^{2+} and functions as a Ca^{2+} sensor (120, 121). It is required for normal signaling of synaptically evoked calcium transients (122) and is involved in synaptic plasticity (123), long-term potentiation (LTP) (124), and memory formation (125, 126), and possibly in the regulation of exocytosis (synaptic secretion of neurotransmitters) (127). Also, in Purkinje cells in the cerebellum, calbindin-D28k appears to be directly involved in motor control (122, 128), which could suggest a possible mechanism explaining motor deficits observed in vitamin D-deficient rats (see below).

Possible linkages to vitamin D in the brain have not been specifically examined for calmodulin, another important calcium-binding protein in the brain (129), although two studies reported that calcitriol treatment shifted the intracellular distribution of calmodulin (130) and that calmodulin is involved in calcitriol-regulated intracellular calcium homeostasis (131) in chick embryo muscle cells. In the brain, calmodulin is involved in neurotransmitter activity (132), NMDA-induced synaptic plasticity (133), and short-term plasticity (transient alteration of the efficiency of synaptic transmission between neurons) (134). Calcium/calmodulin-dependent protein kinase II (CAM kinase II) is highly concentrated in neurons and is believed to play a central role in a variety of brain functions, including learning and memory; it has been suggested that CAM kinase II is the molecular basis of long-term synaptic memory (135–138).

Other effects of calcitriol on intracellular calcium homeostasis

One mechanism by which calcitriol regulates cellular calcium homeostasis is by down-regulating the expression of voltage-sensitive calcium channel transcripts (139, 140), which has been demonstrated in primary rat hippocampal cells (141). Fluxes in intracellular calcium concentration regulate many essential cellular signaling processes throughout the body, including cell cycle progression, apoptosis, and transcription (142–144). In the brain, neuronal firing depends on intracellular calcium flux, which also appears to play an important role in developmental processes, including neurogenesis, synaptogenesis, myelination, and neurotransmitter release (142, 145–147). In addition, disturbed calcium homeostasis is a characteristic of the neurotoxicity of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) (76). Effects on L-type voltage-sensitive calcium channels and neuroprotection were observed to occur at the same concentrations of calcitriol treatment (148). Increased L-type voltage-sensitive calcium channel current is associated with neuron aging; treatment of aged rats with calcitriol restored current activity to that seen in younger animals (141).

Neurogenesis is stimulated by calcitriol and some of its target gene products

As discussed in several reviews (14, 149–151), calcitriol acts as a prodifferentiation hormone in many tissues. With reference to the brain, it is of interest that the increase in apoptotic cells and decrease in mitosis in the developing rat brain correlates with the appearance of VDR (64). Chronic treatment with calcitriol or its analogs increased neurite outgrowth (and some other markers of differentiation) in human neuroblastoma cells in some experiments (61, 152), but not others (153, 154), possibly due to the use of different neuroblastoma cell lines (153). In rodents, calcitriol treatment stimulated neurite outgrowth in embryonic hippocampal explant cultures (155) and in a hippocampal progenitor cell line (156).

Some vitamin D target gene products have also been observed to stimulate neurite outgrowth in rodent brain cells *in vitro*. For example, GDNF treatment of embryonic striatal (93) or ventral mesencephalic (91) cells resulted in biochemical and morphological evidence of differentiation. In rodent systems, overexpression of calbindin-D28k resulted in neurite outgrowth of dopaminergic neuronal cells (157) and hippocampal progenitor cells (158).

Adult neurogenesis is a very active area of research (159, 160). Adult stem cells are believed to be located in only two regions of the adult brain. One group of neural stem cells originates in the subventricular region of the forebrain and migrates to the olfactory bulb; the second group originates in the subgranular zone of the hippocampus and differentiates into neural and glial cells in the dentate gyrus (161, 162). In both cases, new neurons are local-circuit interneurons that link motor and sensory neurons (163).

To our knowledge, the possible involvement of calcitriol in adult neurogenesis has not been examined. It is of interest that VDR appear to be essential for the function of at least one type of non-neural stem cell (keratinocyte stem cells) (164). With specific reference to the brain, VDR are widespread in both the olfactory bulb and the dentate gyrus in rodents (65) and were recently observed in the subventricular zone of the neonatal brain (165). Furthermore, an increased density of hippocampal neurons was observed in some rat strains supplemented for 6–12 mo with calcitriol (20 ng/rat, administered subcutaneously 5×/wk) (166). Collectively, this evidence suggests the possibility that calcitriol could stimulate adult neurogenesis.

Morphological and biochemical effects of vitamin D restriction

Some morphological and biochemical changes were observed in the brains of newborn Sprague-Dawley rats whose serum 25OHD3 levels were >90% lower than controls after dams were restricted for dietary vitamin D and UV radiation 6 wk prior to and during pregnancy (167). These changes included a longer cortex and enlarged ventricles, reduced expression of NGF and GDNF, and the low-affinity p75 receptor (83), an increased number of mitotic cells, and a decreased number of apoptotic cells (168). Using the same dietary restriction protocol, at 10 wk of age, enlarged ventricles and reduced expression of nerve growth factor were also observed (169). In an experiment in which 3-wk-old rats were fed a vitamin D-deficient diet for 4 wk, one-half of the animals were also injected i.p. with calcitriol (300 ng/100g b.w.) (170). In the diet-restricted groups not injected with calcitriol, results included decreased phosphorus and increased citrate concentrations in cortical homogenates, increased acetylcholinesterase, glucose-6-phosphate dehydrogenase, and acyl phosphatase activities in cortical synaptosomes, and increased NAD^+-dependent isocitrate dehydrogenase in cortical mitochondria. None of these changes occurred in the diet-restricted groups injected with calcitriol (170). Finally, reduced concentrations of brain calcium (10–24%) were observed in vitamin D diet-restricted rats under conditions that resulted in a 50% reduction in serum calcium (171).

EVIDENCE THAT LINKS VITAMIN D INADEQUACY TO COGNITIVE OR BEHAVIORAL DYSFUNCTION

Humans

A possible linkage of low vitamin D to schizophrenia was hypothesized (172) and reviewed by J. J. McGrath and colleagues (173–175). Evidence includes the association of schizophrenia with winter births, its greater

frequency in dark-skinned migrants to cold climates, and the variation in incidence and prevalence of schizophrenia with latitude (172, 175, 176). It is also noteworthy, as investigators point out (83), that two morphological changes observed in the brains of rats diet-restricted for vitamin D (see above) are enlarged ventricles and a thinner cortex, both of which are consistent with changes consistently observed in the brains of humans with schizophrenia (177). Two small studies directly tested for an association between low $25OHD_3$ and schizophrenia in humans (178, 179). One of these studies (179) retrospectively compared the use of vitamin D supplements during the first year of life with subsequent development of schizophrenia. A significantly reduced risk of developing schizophrenia was observed in males who consumed supplements, but not in females (179). The second study (178) compared $25OHD_3$ concentrations in banked sera from the third trimester of mothers of offspring with schizophrenia and healthy controls, and concluded that results in an African-American subgroup (only 7 individuals) were suggestive of an association, although it was not statistically significant. Another study (180) searched for VDR gene variants in a small ($n=100$) population of individuals with schizophrenia. Two of 14 African-American patients contained a novel variant compared to none in African-American controls; the result was not significant, but was suggestive ($P=0.08$). Studies examining VDR polymorphisms (181) and cosegregation of psychosis and rickets phenotypes in an inbred family (182) were also negative.

The initial suggestion that low vitamin D might be linked to depression was based on the higher incidence of seasonal affective disorder (SAD) in winter, when exposure to UV in sunlight is low (183). Currently, the most effective treatment for SAD is treatment with bright light that does not include UV (184). Most current research assumes that SAD is a circadian disorder and that light acts through the eye (185–187), although this has not been proven. One randomized controlled trial (RCT) that specifically tested for the effectiveness of vitamin D2 treatment (10^5 IU, single dose) on SAD patients reported positive results (188). Four other RCTs compared measures of perceived well-being before and after treatment with vitamin D3, with mixed results: positive (1000 IU/day for 6 mo (189), 400–800 IU/day for 5 days (190); negative (800 IU/day for 6 mo (191), 1000 IU/day for 6 mo (192). It is difficult to directly compare these RCTs since patient populations, supplementation protocols, durations, and endpoints differed. A recent small ($n=80$) cross-sectional study reported an association between lower serum concentrations of $25OHD_3$ and depression in a group with mild symptoms of Alzheimer's disease (AD) compared to normal controls (193), but since neither subjects nor controls were institutionalized, it is difficult to rule out obvious confounders such as less exposure to sunlight in the AD group. Thus, while the

seasonal and latitudinal associations of SAD are intriguing observations and are to some extent supported by RCTs, results are mixed.

We also note several additional recent studies in humans: 1) an interesting report of differences in performance of 563 elderly participants on tests measuring several aspects of cognitive function and depression associated with specific VDR polymorphisms (194); 2) a higher frequency of a VDR polymorphism in Alzheimer patients ($n=104$) compared to age-matched controls (195); and 3) a significant positive correlation ($P<0.01$) between serum 25OHD3 concentrations and scores on the minimental state examination (MMSE) (a performance test assessing cognitive function) in a retrospective chart review of data obtained on 32 older adults referred to a clinic because of symptoms of dementia; the study did not consider potential confounders, such as the possibility that greater degrees of dementia might result in less sun exposure (196).

Rodents

Motor activity and cognitive or behavioral effects were examined using two experimental systems, both designed to impair ability to utilize vitamin D during brain development. One system utilizes Sprague-Dawley rats made vitamin D deficient using dietary and UV radiation restriction (197–203), resulting in a greater than 90% reduction in serum 25OHD3 concentration in neonates (83). The second system uses mice containing defective VDR that bind calcitriol but cannot bind to DNA (43) (VDR-KO mice) (204–212). VDR-KO mice appear normal in growth rate until after weaning, when they develop a phenotype similar to Type II hereditary rickets in humans (28, 42, 213, 214). The animals usually die by 15 wk of age unless they are fed a special diet (215).

In a series of studies, A. V. Kalueff, who has discussed his work in several recent reviews (38, 68, 84), reported that VDR-KO offspring exhibit a variety of behavioral abnormalities, including aberrant grooming (205, 208, 209) and nest-building activities (206, 210), neglectful or cannibalistic maternal behavior, and submissive social behavior (206). Using the dietary restriction model, an Australian group (J. J. McGrath, D. W. Eyles, A. Mackay Sim, and collaborators) reported several other abnormalities, including hyperlocomotion in the holeboard or open-field tests (199, 201), the absence of latent inhibition in a shuttle-box test (197), and less habituation as measured by head-dipping in the holeboard test (197, 198). On the basis of these results, the Australian group recently suggested that the gestational vitamin D dietary restriction design may be a useful model for studying mechanisms of schizophrenia (198, 201).

Although a detailed critical analysis of all of these studies is beyond the scope of this review, we raise several issues below that suggest that further work is needed to definitively establish that effects observed are

TABLE 2. *Activity and cognitive or behavioral tests of vitamin D-restricted rats or VDR knockout mice*

	Investigator-reported results[a]	
Test	Positive	Negative
Exploratory and activity tests[b]	Open field: <u>*less distance traveled and/or less rearing*</u> (203–205)[c] (216); *greater distance traveled and more rearing* (201) Bedding/nest-building tests: <u>impaired digging activity</u> (204); <u>less paper damage and less accurate nests</u> (206, 210) Marble burying test: <u>fewer marbles buried</u> (204) Swimming behavior: <u>more immobility, sinking, rotations</u> (207); <u>reduced ability to float</u> (211) Light-dark box: <u>less exploration of the light area</u> (205)	*Stabilimeter* (216) *Forced swim test* (199) Y-maze: <u>distance traveled, time spent in each arm, arm entries</u> (204) <u>Actometer</u> (205, 207, 208) <u>Food finding</u> (205, 208) <u>Object finding</u> (205, 207)
	Holeboard: *fewer head dips at baseline and less habituation*[d] (197, 198); <u>less distance traveled</u> (205, 208); *more distance traveled (birth group only)*[e] (199, 202); <u>fewer head dips</u> (205) Rotarod: <u>shorter time on the rotarod</u> (204)	Holeboard: <u>*head dips*</u> (199, 202, 208); <u>*distance*</u> (197, 198); *weaning and life groups only* (199)[e] <u>Horizontal bar test</u> (205)
Spatial learning	Radial maze: *more time in the maze* (216)	*Radial maze* (197) *T-maze reversal* (216) <u>Y-maze</u> (212)
Conditioned learning	Shuttle box: *more avoidance reactions in initial training* (197) Brightness discrimination: *fewer errors after 24 h retention interval* (197)	
Anxiety[f]	<u>*Elevated plus maze*</u> (199); *birth group only* (205) <u>Longer latency to eat novel food</u> (212)	<u>*Elevated plus maze*</u> (199, 204, 208) *weaning and life groups*[e]
Developmental measures	<u>Shorter gait</u> (204) Vertical screen: <u>shorter retention time</u> (207)	Developmental signs: *self-righting reflex, posture* (203), <u>*SHIRPA screen*</u> (204)
Other behavioral	Grooming behavior: <u>increased grooming activity</u> (205, 208); <u>abnormal grooming sequence</u> (209) Tail suspension (depression test): <u>*longer* latency to immobility</u> (206) Social confrontation: <u>more submissive</u> (206) Aberrant maternal behavior: <u>neglect, cannibalism</u> (206) Acoustic startle: *impaired PPI at 10 wk*[g] (200); <u>lower PPI scores at long, but not short, prepulse to pulse interval times</u> (204)	<u>*Grooming activity*</u> (202, 211) <u>*Social interaction with nonaggressive mice*</u> (199, 206) <u>Two-bottle preference gustatory test</u> (212) <u>Buried food pellet olfactory test</u> (212) Acoustic startle: *n.s. at 5 wk* (200); *n.s. at 10 wk* (199, 202)

[a]Results obtained using a UV radiation and dietary vitamin D restriction model are in italics, and results obtained using VDR-KO mice are underscored. Note that results that are in italics and underscored were obtained using both systems. [b]Open field, light-dark box, and holeboard tests are usually considered to have an anxiety component, but they also have significant exploratory and activity components, and for those reasons are listed in that section of the table, but cross-referenced in the Anxiety section. [c]O'Loan *et al.* (203) was primarily aimed at examining effects of MK-801 on activity. Examination of Fig. 2 in that article suggests that, among controls not injected with MK-801, the vitamin D-restricted group traveled less distance than nonrestricted animals, though investigators do not discuss this finding. [d]Investigators reported that the vitamin D-restricted group demonstrated less habituation than controls because head-dipping decreased over time in controls, but remained relatively constant in the test group. We note that, in both experiments (197, 198), the restricted group had fewer head dips than controls at all time points examined, which could suggest a more complex interpretation. [e]Groups in this study were birth group, deprived of dietary vitamin D from prior to gestation to birth; weaning group, deprived of vitamin D prior to gestation through PND21; and life group, deprived of vitamin D from prior to gestation to PND70. [f]See also results for the holeboard, open field, and light-dark box tests in the Exploratory and Activity Tests section above. [g]Positive result only in the life group; other groups were negative.

independently reproducible and that they are directly related to brain development. Results reported for all of the activity or behavioral endpoints examined using both models are summarized in **Table 2**. Experiments using the dietary restriction and VDR-KO models cannot, strictly speaking, be directly compared because of obvious species and protocol differences. However,

since both models severely limit the ability of the organism to utilize vitamin D during brain development, it is useful to consider whether similar performance endpoints are affected. Therefore, Table 2 is organized by type of test rather than experimental system. For clarity, experiments using the dietary restriction model are in italics, and those using VDR-KO

mice are underscored. Several observations are apparent from an examination of Table 2.

First, some results appear to have been inconsistently observed. *1*) Hyperlocomotion, measured as "distance traveled" in holeboard or open-field tests, was inconsistently observed using the gestational dietary restriction protocol, as also noted by investigators (202). Specifically, greater distance traveled was reported in several studies (199, 201, 202) but not observed in other studies from the same laboratory using the same gestational dietary restriction protocol (197, 198). Furthermore, less distance traveled was observed in an older dietary restriction study involving adult rats (216), and no differences were observed if the period of dietary restriction was extended beyond birth (199). Using VDR-KO mice, less distance traveled was observed in all three experiments from both laboratories that examined this endpoint (204, 205, 208). *2*) Several reports of altered grooming activity in VDR-KO mice from the Kalueff group (205, 208, 209) are in apparent contrast to reports of normal grooming activity from the Australian group using the same VDR-KO mutant (204, 211). The two experiments were not identical, and the different results could be due to a variety of factors, including the somewhat larger group sizes in the positive study; its use of only males (*vs.* mixed sex groups), animals with an isogenic (*vs.* mixed) genetic background, and use of different dietary methods to rescue VDR-KO offspring. *3*) Other differences in results obtained using the dietary restriction and VDR-KO systems are also evident in Table 2. These differences could be due to many factors, including differential effects in the two models on ability to utilize vitamin D, differences between rats and mice, or other methodological differences. However, since all protocols (with one exception (216)) should have resulted in vitamin D inadequacy during development, the lack of consistency makes it difficult to conclude there is a clear effect on these endpoints.

Second, only a few tests were specifically targeted at learning. Results in several spatial learning tests were predominantly negative (197, 212, 216). A brightness discrimination test suggested that vitamin D-restricted animals performed *better* than controls in a relearning task (197), and a test for latent inhibition in a shuttle box test was positive (197).

Third, potential confounders were not, in general, assessed in the studies reviewed. For example, VDR-KO offspring appear normal in growth rate and behavior until after weaning, when they develop a phenotype similar to Type II hereditary rickets in humans (28, 42, 213, 214). The animals usually die by 15 wk of age unless they are fed a special diet supplemented with calcium, phosphorus, and lactose (215). In studies from A.V. Kalueff and colleagues, this antirachitic diet was used (*e.g.*, ref. 207); in studies from J. J. McGrath, D. W. Eyles, A. Mackay-Sim, and colleagues, a normal diet supplemented with calcium was used (*e.g.*, ref. 204). Since virtually all performance tests required movement and since it is not clear to what degree these diets attenuated the rachitic phenotype, conclusions of effects on brain function based on tests requiring movement must be considered uncertain, as has been pointed out (211). In addition, the VDR-KO phenotype is characterized by alopecia, which, in the absence of information on effects of nonvitamin D related alopecia on grooming, must be considered a potential confounder.

ARE CAUSAL CRITERIA SATISFIED?

We have previously used five causal criteria (slightly adapted from the original formulation; ref. 217) to evaluate the strength of evidence linking the availability of a micronutrient to cognitive or behavioral function (2–4). These criteria are: *1*) a plausible biological rationale, *2*) a consistent association, *3*) specificity of cause and effect, *4*) a dose-response relationship (*i.e.*, demonstrating that the intensity of effect depends on the degree of deficiency or supplementation), and *5*) ability to experimentally manipulate the effect (*e.g.*, reversibility of effects).

On the basis of the experiments reviewed above, the criterion most convincingly satisfied is a *plausible biological rationale*. Evidence includes the widespread presence of VDR and 1,α-hydroxylase (the terminal rate-limiting enzyme in the synthesis of calcitriol) in the developing and adult brain, and the known involvement of some calcitriol target gene products (*e.g.*, the neurotrophins NGF, NT-3, and NT4/5; GDNF; and the calcium-binding proteins calbindin-D28k, parvalbumin, calretinin, and possibly calmodulin) and calcitriol-regulated processes (*i.e.*, L-type voltage-gated calcium channels) in critical functions required for cognition and behavior.

Among the studies that examined possible *associations* between vitamin D inadequacy or treatment and cognitive or behavioral performance in humans or rodents, some evidence of association is provided, but, as discussed above, effects are subtle and some results have not yet been replicated, suggesting more work is needed (see Discussion and Conclusions). *Specificities of cause and effect* pertain to potential confounding in experiments that measure disease or performance outcomes, which has not been sufficiently accounted for in the studies reviewed. For example, as investigators point out, the consistent associations of schizophrenia or SAD with winter or northern latitude could obviously be due to many factors other than to lower serum concentrations of 25OHD$_3$. And, altered motor activity of VDR-KO mice, or rats whose dams were subjected to dietary and UV radiation restriction during pregnancy, could be due to effects of vitamin D inadequacy on bone and muscle development (218) rather than to effects in the brain. The evidence base is not yet extensive enough to permit a discussion of the other two causal criteria.

PROINFLAMMATORY CYTOKINE-INDUCED COGNITIVE/BEHAVIORAL DYSFUNCTION: COULD LOW 25OHD3 STATUS BE AN EXACERBATING FACTOR?

As discussed in many reviews, a significant body of evidence suggests that elevated levels of proinflammatory cytokines in the brain can play a causal role in depression (219–234). Cytokines are small proteins synthesized by cells directly involved in immune function, such as macrophages and their counterparts in the brain, microglia, and also by many other nucleated cells in the body. Among a range of functions (*e.g.*, ref. 235), cytokines play a key role in the inflammatory process (236). There are many cytokines; at least 30 interleukins (IL-1, IL-2, etc), and others such as TNF-α, TGF-β, and the interferons (*e.g.*, IFN-γ). Most cytokines can be classified as either proinflammatory or antiinflammatory.

Evidence from a variety of systems supports the proinflammatory cytokine theory of depression, first proposed some 25 years ago (237). In humans, support is provided from studies of clinical depression, sickness behavior resulting from infection, illnesses accompanied by inflammation (*e.g.*, autoimmune diseases, heart disease, osteoporosis), chemotherapy, or experimental treatments with endotoxin. Supporting studies in animals involve treatment with proinflammatory cytokines or use of rodent models of human inflammatory diseases (*e.g.*, experimental immune encephalitis, a model of MS, or the streptozotocin model of type 1 diabetes).

Primary evidence (see reviews cited above for specific references) includes *1)* associations or correlations between the severity of depression and increased concentrations of inflammatory markers; *2)* several plausible mechanisms based on observations that proinflammatory cytokines alter neurotransmitters, neuropeptides, and the HPA axis, which are also altered in depression; *3)* evidence that depression is induced in patients with cancer or infectious diseases by cytokine therapy with IFN-α, which induces other proinflammatory cytokines; *4)* evidence that psychological stress, known to be strongly associated with depression, induces proinflammatory cytokines; *5)* evidence that antidepressants and some other treatments for depression are anti-inflammatory; *6)* controlled experiments in humans treated with endotoxin that demonstrate cognitive/behavioral effects; and *7)* experiments in rodents demonstrating that cognitive dysfunction or depressive-like behavior can be elicited by treatment with proinflammatory cytokines such as IL-1β and prevented by antagonists (*e.g.*, refs. 238–241).

Calcitriol's complex, and still incompletely understood, interactions with the immune system have been discussed in many expert reviews (*e.g.*, refs. 31, 36, 242–244). Discussion of these interactions is beyond the scope of this review. However, important elements in calcitriol's spectrum of function appear to be the modulation of enhanced cellular immune response pathways (Th1) or autoimmune (loss of tolerance) responses. Thus, calcitriol appears to participate in regulating Th1:Th2 balance by down-regulating the Th1 pathway, promoting the Th2 pathway, and promoting tolerance by enhancing the production of T regulatory cells. These regulatory shifts are accomplished in part by decreasing the production of proinflammatory cytokines and increasing the production of antiinflammatory cytokines.

There is considerable direct evidence for a modulatory effect of calcitriol treatment on proinflammatory cytokines both *in vitro* and *in vivo*. A few examples are listed: *1)* decreased production of proinflammatory cytokines (or increased production of anti-inflammatory cytokines) in a variety of cell types; examples include monocytes (245–247), microglia (an important source of proinflammatory cytokines in the brain) (248), keratinocytes (249, 250), endothelial cells (251), and human benign prostatic hyperplastic cells (252); *2)* decreased serum concentrations of the proinflammatory cytokine TNF-α and increased concentrations of the antiinflammatory cytokine IL-10 in a recent randomized controlled trial (RCT) involving vitamin D3 supplementation of congestive heart failure patients (253); *3)* decreased TNF-α levels and suppressed disease symptoms in a rodent model of inflammatory bowel disease (IBD) after treatment with calcitriol and calcium (254); *4)* higher levels of proinflammatory cytokines in VDR-KO mice, which are more susceptible to induced IBD (255); and *5)* an inverse correlation of 25OHD3 status with inflammation markers in a study of 171 healthy adults (256) and a positive correlation with IL-10 (an antiinflammatory cytokine) concentrations in cord blood (257).

The down-regulation by calcitriol of NF-κB, a central mediator of inflammation, (see reviews cited above) (258) is also consistent with calcitriol's modulatory effect on proinflammatory states. NF-κB is induced in the brain following treatment with the proinflammatory cytokine IL-1 and is believed to mediate its adverse behavioral effects (259). Increased concentrations of NF-κB are also linked to increased stress in humans (260) and to stress-induced neuronal cell loss in rodents (261).

While cytokine signals from the periphery can be transmitted to the brain *via* the circumventricular organs or vagal afferents (262, 263), a key question is whether calcitriol can also directly modulate proinflammatory cytokine production in the brain. Calcitriol is known to be synthesized by microglial cells (264), which are the primary mediators of proinflammatory immune responses in the brain (265–267). Calcitriol has been observed to inhibit the synthesis of proinflammatory cytokines in a microglial cell line (248). In addition, oral treatment with 25OHD3 reduced IL-1β production in the rat hippocampus (268).

The possible relationship of low 25OHD3 status to disease-associated depression has, so far as we are aware, only been examined in one small study of anxiety and depression in fibromyalgia patients (269), which observed a significant relationship. It is well known that poor 25OHD3 status is common in many

human diseases associated with inflammation, including infection, autoimmune diseases, obesity and metabolic syndrome, type 2 diabetes, osteoporosis, cancer, and cardiovascular diseases (33, 35, 41, 193, 269–293). Depression is not uncommon in these diseases, which is the subject of a very large experimental literature; a few recent examples are cited: multiple sclerosis (294–297), type 1 diabetes (298–301), rheumatoid arthritis (221, 302), lupus erythrematosus (303, 304), inflammatory bowel disease (IBD) (305–308), obesity and metabolic syndrome (309–311), type 2 diabetes (312–314), osteoporosis (315–317), cancer (318, 319), cardiovascular disease (320), infection (321), and fibromyalgia (269, 322). In this literature, the possible involvement vitamin D has not been discussed, so far as we are aware.

DISCUSSION

The primary goal of this review is to provide an overview of evidence relevant as to whether vitamin D availability affects cognition or behavior. As summarized in the body of the review, evidence that calcitriol is involved in both brain development and function is strong, on the basis of studies involving biochemical or other biological endpoints, as also reviewed by others

(30, 37–39). Evidence from studies directly measuring cognitive or behavioral endpoints is suggestive, but less clear-cut, as summarized in **Fig. 1**. As we discuss, a number of studies in humans and rodents that directly examined effects of vitamin D inadequacy or supplementation on cognitive or behavioral performance individually suggest subtle cognitive and/or behavioral changes (179, 188–190, 193, 194, 196–199, 201–212, 216). However, examination of these latter studies as a group using several causal criteria suggests that the evidence base does not yet appear to be sufficient to conclude with certainty that there is a causal connection.

The inconclusiveness of the human studies is not particularly surprising, given their small number and the many difficulties involved in conducting human trials. However, it is curious that results of rodent studies are not stronger and more consistent, since rodents afford the opportunity for more flexibility in design and ability to control experimental variables than can be achieved in human studies. If calcitriol plays an important role in brain development and function, one might have predicted that performance deficits would be more obvious, particularly in the studies using a severe dietary restriction model or VDR-KO mice (see Table 2 and text).


Figure 1. Vitamin D, proinflammatory cytokines, and cognitive or behavioral dysfunction. Types of evidence from human or rodent studies that link cognitive and behavioral performance to vitamin D adequacy, proinflammatory cytokine status, and inflammation-associated diseases. See text for discussion and citations.

Several observations suggest that additional research may help to explain this apparent paradox. First, a relatively small number of cognitive/behavioral tests have been conducted. If individual neural systems are affected by vitamin D inadequacy, tests specifically targeted at those systems may be required to achieve sufficient sensitivity to detect an effect (323, 324). Second, it is possible, given the importance of vitamin D in so many aspects of mammalian biology, that there are homeostatic and/or back-up mechanisms that protect vital organs, such as the brain, from loss of calcitriol-regulated functions. This may be particularly true in rodents, who are covered with fur and primarily nocturnal. In this regard, the recent observation that lithocholic acid can substitute for vitamin D under deficiency conditions in rodents is potentially relevant (53). Third, effects observed in all *in vivo* rodent studies that demonstrated effects of calcitriol treatment on gene expression in the brain used relatively high doses of calcitriol (69, 73, 76, 77, 107, 111); some of these studies injected calcitriol directly into the brain (69, 76, 77). The only study that used vitamin D_3 instead of calcitriol (111) treated animals by gastric cannulation with 20,000 IU/kg/day for 4 mo. It is possible that effects resulting from these high-dose treatments do not occur under physiological conditions. However, calcitriol is believed to exert its effects in an autocrine or paracrine manner, even within tiny "nanodomains" within the cell (23, 25). Hence, the classical concept of "concentration" may not apply, and very high concentrations of calcitriol may be delivered subcellularly under normal physiological conditions. Fourth, there are very few studies that examined effects of vitamin D deficiency on gene expression (21, 82). And, we are also not aware of any studies in rodents that examined effects of calcitriol treatment on cognitive or behavioral performance. These experiments seem important to do. And fifth, with respect to use of VDR-KO strains, some critical vitamin D-regulated functions during fetal and neonatal brain development could involve non-VDR-mediated mechanisms (22). Also, other VDR knockout strains are available (28, 213), as are 1,α-hydroxylase-knockout strains (325–327), which might be productive to explore as alternative models.

Additional suggested areas for research

The independent associations of inflammation, low 25OHD3 status, and cognitive or behavioral dysfunction in a number of human diseases are intriguing. To our knowledge, a possible relationship between 25OHD3 status and disease-associated depression has only been addressed experimentally in one small study of fibromyalgia patients, with encouraging results (269). We also note that the broad spectrum of calcitriol's functions (*e.g.*, effects on cell proliferation and differentiation) have suggested the use of calcitriol and its analogues to treat cancer and autoimmune diseases (currently the only therapeutically recommended use

of calcitriol is for treatment of psoriasis) (328, 329). Some analogues, as well as calcitriol, are effective in treating a variety of cancers and autoimmune diseases in model systems (*e.g.*, refs. 254, 330–332). It would be of interest to include cognitive and behavioral endpoints, in addition to primary disease endpoints, in future human trials and rodent studies using disease models.

Rickets is the only human disease that is known to be caused by vitamin D deficiency during early postnatal life, a critical period of brain development (218). To our knowledge, no studies have examined cognitive or behavioral function in children with rickets. We have also been unable to locate any studies that have measured inflammatory markers in children with rickets. While overt symptoms of mental dysfunction in rickets patients would most likely have been noticed, cognitive or behavioral deficits resulting from nutritional inadequacies are frequently subtle and require focused testing to detect (*e.g.*, refs. 2, 4).

Public health issues

Vitamin D inadequacy is largely based on whether circulating concentrations of 25OHD3 are below certain cutoff levels (14). There is a great deal of discussion and uncertainty as to what cutoff levels should be used (35, 333–336). For example, in surveys of >18,000 individuals in the United States (337) and >7000 individuals in the United Kingdom (338), inadequacy was calculated using several different 25OHD3 cutoff values, resulting in prevalence estimates ranging from 3 to 57% (337) or 15.5 to 87.1% (338) for adult men and women. Prevalence estimates are much higher for some other groups, including the elderly (337, 339) and African-Americans, who are 2–8 times more likely to be insufficient compared to age-matched Caucasians (340–342). The lower end of the prevalence estimate ranges indicate minimum 25OHD3 concentrations required to prevent rickets (14). The higher end of the ranges reflect opinions of a number of experts based on recent data concerning 25OHD3 concentrations required to decrease fracture risk or to prevent or mitigate certain forms of cancer (41, 335, 343), as well as evidence suggesting that vitamin D can be tolerated at higher levels than formerly thought (35, 334–336). It has been suggested that research to determine what concentrations of 25OHD3 are required to optimize these and other functions of calcitriol should be a high priority (*e.g.*, refs. 41, 270, 334).

The involvement of calcitriol in brain function only serves to underline the importance of ensuring an adequate supply of vitamin D, as has been pointed out (*e.g.*, refs. 38, 82). It remains to be seen to what degree evidence for this involvement can be translated into quantitative information relevant to setting adequacy requirements. Clearly relevant, if they can be more consistently replicated, are studies suggesting that depression may be linked to lower concen-

trations of 25OHD3 (183, 188–190, 193, 196, 269). However, in our opinion, it is uncertain whether cognitive/behavioral endpoints, which are inherently difficult to quantify and are often nonspecific (323), are amenable to the level of precision required to optimize 25OHD3 concentrations. Other more readily quantifiable markers of altered brain function would be highly desirable.

CONCLUSIONS

While mechanistic and biological evidence strongly suggests that calcitriol is involved in brain development and critical brain functions, it has proved more difficult experimentally to demonstrate obvious effects of vitamin D inadequacy on cognitive or behavioral endpoints. Although there is some limited evidence for a relationship between vitamin D inadequacy and depression, or possibly schizophrenia, studies are relatively few in number and results are mixed. The evidence base in rodents is larger, with two laboratories providing intriguing and clearly suggestive, though in our opinion not definitive, evidence of subtle behavioral effects of vitamin D inadequacy. Despite residual uncertainty, we believe the evidence overall suggests that supplementation to ensure adequacy is prudent, particularly for groups whose 25OHD3 status is exceptionally low, including nursing infants, the elderly, and African-Americans. Such supplementation is already recommended to protect against rickets, fracture risk, and possibly some forms of cancer.　　　　　FJ

REFERENCES

1. Bryan, J., Osendarp, S., Hughes, D., Calvaresi, E., Baghurst, K., and van Klinken, J. W. (2004) Nutrients for cognitive development in school-aged children. *Nutr. Rev.* **62,** 295–306
2. McCann, J. C., and Ames, B. N. (2005) Is docosahexaenoic acid, an n-3 long chain polyunsaturated fatty acid, required for the development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. *Am. J. Clin. Nutr.* **82,** 281–295
3. McCann, J. C., Hudes, M., and Ames, B. N. (2006) An overview of evidence for a causal relationship between dietary availability of choline during development and cognitive function in offspring. *Neurosci. Biobehav. Rev.* **30,** 696–712
4. McCann, J. C., and Ames, B. N. (2007) An overview of evidence for a causal relationship between iron deficiency during development and cognitive or behavioral function in children. *Am. J. Clin. Nutr.* **85,** 931–945
5. Benton, D. (2001) Micro-nutrient supplementation and the intelligence of children. *Neurosci. Biobehav. Rev.* **25,** 297–309
6. TheNemoGroup. (2007) Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: two parallel, randomized, placebo-controlled studies in Australia and Indonesia. *Am. J. Clin. Nutr.* **86,** 1082–1093
7. Siega-Riz, A. M., and Popkin, B. M. (2001) Dietary trends among low socioeconomic status women of childbearing age in the United States from 1977 to 1996: a comparison among ethnic groups. *J. Am. Med. Womens Assoc.* **56,** 44-48, 72
8. Lee, J. S., and Frongillo, E. A., Jr. (2001) Nutritional and health consequences are associated with food insecurity among U.S. elderly persons. *J. Nutr.* **131,** 1503–1509
9. Dixon, L. B., Winkleby, M. A., and Radimer, K. L. (2001) Dietary intakes and serum nutrients differ between adults from food-insufficient and food-sufficient families: Third National Health and Nutrition Examination Survey, 1988–1994. *J. Nutr.* **131,** 1232–1246
10. Ames, B. N. (2005) Increasing longevity by tuning-up metabolism. *EMBO Rep.* **6,** S20–S24
11. Ames, B. N., Atamna, H., and Killilea, D. W. (2005) Mineral and vitamin deficiencies can accelerate the mitochondrial decay of aging. *Mol. Aspects Med.* **26,** 363–378
12. Ames, B. N. (2006) Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. *Proc. Natl. Acad. Sci. U. S. A.* **103,** 17589–17594
13. Holick, M. F. (2003) Vitamin D: a millenium perspective. *J. Cell. Biochem.* **88,** 296–307
14. NAS/DRI (1997) *Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride*, National Academy Press, Washington, D.C.
15. Houghton, L. A., and Vieth, R. (2006) The case against ergocalciferol (vitamin D2) as a vitamin supplement. *Am. J. Clin. Nutr.* **84,** 694–697
16. Wang, T. T., Tavera-Mendoza, L. E., Laperriere, D., Libby, E., MacLeod, N. B., Nagai, Y., Bourdeau, V., Konstorum, A., Lallemant, B., Zhang, R., Mader, S., and White, J. H. (2005) Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. *Mol. Endocrinol.* **19,** 2685–2695
17. Norman, P. E., and Powell, J. T. (2005) Vitamin D, shedding light on the development of disease in peripheral arteries. *Arterioscler. Thromb. Vasc. Biol.* **25,** 39–46
18. Hannah, S. S., and Norman, A. W. (1994) 1 alpha,25(OH)2 vitamin D3-regulated expression of the eukaryotic genome. *Nutr. Rev.* **52,** 376–382
19. Segaert, S., and Bouillon, R. (1998) Vitamin D and regulation of gene expression. *Curr. Opin. Clin. Nutr. Metab. Care* **1,** 347–354
20. Savli, H., Aalto, Y., Nagy, B., Knuutila, S., and Pakkala, S. (2002) Gene expression analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells: a cDNA array study. *Br. J. Haematol.* **118,** 1065–1070
21. Eyles, D., Almeras, L., Benech, P., Patatian, A., Mackay-Sim, A., McGrath, J., and Feron, F. (2007) Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. *J Steroid Biochem. Mol. Biol.* **103,** 538–545
22. Ebert, R., Schutze, N., Adamski, J., and Jakob, F. (2006) Vitamin D signaling is modulated on multiple levels in health and disease. *Mol. Cell. Endocrinol.* **248,** 149–159
23. Norman, A. W. (2006) Vitamin D receptor (VDR): new assignments for an already busy receptor. *Endocrinology* **147,** 5542–5548
24. Hendy, G. N., and Goltzman, D. (2005) Does calcitriol have actions independent from the vitamin D receptor in maintaining skeletal and mineral homeostasis? *Curr. Opin. Nephrol. Hypertens.* **14,** 350–354
25. Boyan, B. D., Wang, L., Wong, K. L., Jo, H., and Schwartz, Z. (2006) Plasma membrane requirements for 1alpha,25(OH)2D3 dependent PKC signaling in chondrocytes and osteoblasts. *Steroids* **71,** 286–290
26. Rohe, B., Safford, S. E., Nemere, I., and Farach-Carson, M. C. (2006) Regulation of expression of 1,25D(3)-MARRS/ERp57/ PDIA3 in rat IEC-6 cells by TGFβ and 1,25(OH)(2)D(3). *Steroids* **70,** 458–463

27. Jia, Z., and Nemere, I. (1999) Immunochemical studies on the putative plasmalemmal receptor for 1,25-dihydroxyvitamin D3 II. Chick kidney and brain. *Steroids* **64,** 541–550

28. Erben, R. G., Soegiarto, D. W., Weber, K., Zeitz, U., Lieberherr, M., Gniadecki, R., Moller, G., Adamski, J., and Balling, R. (2002) Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. *Mol. Endocrinol.* **16,** 1524–1537

29. Hughes, P. J., and Brown, G. (2006) 1Alpha,25-dihydroxyvitamin D3-mediated stimulation of steroid sulphatase activity in myeloid leukaemic cell lines requires VDRnuc-mediated activation of the RAS/RAF/ERK-MAP kinase signalling pathway. *J. Cell. Biochem.* **98,** 590–617

30. Garcion, E., Wion-Barbot, N., Montero-Menei, C. N., Berger, F., and Wion, D. (2002) New clues about vitamin D functions in the nervous system. *Trends Endocrinol. Metab.* **13,** 100–105

31. Deluca, H. F., and Cantorna, M. T. (2001) Vitamin D: its role and uses in immunology. *FASEB J.* **15,** 2579–2585

32. Lin, R., and White, J. H. (2004) The pleiotropic actions of vitamin D. *Bioessays* **26,** 21–28

33. Nagpal, S., Na, S., and Rathnachalam, R. (2005) Noncalcemic actions of vitamin D receptor ligands. *Endocrinol. Rev.* **26,** 662–687

34. Raiten, D. J., and Picciano, M. F. (2004) Vitamin D and health in the 21st century: bone and beyond. Executive summary. *Am. J. Clin. Nutr.* **80,** 1673S–1677S

35. Zittermann, A. (2003) Vitamin D in preventive medicine: are we ignoring the evidence? *Br. J. Nutr.* **89,** 552–572

36. Dusso, A. S., Brown, A. J., and Slatopolsky, E. (2005) Vitamin D. *Am. J. Physiol. Renal Physiol.* **289,** 8–28

37. McGrath, J., Feron, F., Eyles, D., and Mackay-Sim, A. (2001) Vitamin D: the neglected neurosteroid? *Trends Neurosci.* **24,** 570–572

38. Kalueff, A. V., and Tuohimaa, P. (2007) Neurosteroid hormone vitamin D and its utility in clinical nutrition. *Curr. Opin. Clin. Nutr. Metab. Care* **10,** 12–19

39. Kalueff, A. V., Minasyan, A., and Tuohimaa, P. (2005) Anticonvulsant effects of 1,25-dihydroxyvitamin D in chemically induced seizures in mice. *Brain Res. Bull.* **67,** 156–160

40. Vieth, R. (2006) What is the optimal vitamin D status for health? *Prog. Biophys. Mol. Biol.* **92,** 26–32

41. Giovannucci, E., Liu, Y., Rimm, E. B., Hollis, B. W., Fuchs, C. S., Stampfer, M. J., and Willett, W. C. (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. *J. Natl. Cancer Inst.* **98,** 451–459

42. Yoshizawa, T., Handa, Y., Uematsu, Y., Takeda, S., Sekine, K., Yoshihara, Y., Kawakami, T., Arioka, K., Sato, H., Uchiyama, Y., Masushige, S., Fukamizu, A., Matsumoto, T., and Kato, S. (1997) Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. *Nat. Genet.* **16,** 391–396

43. Bula, C. M., Huhtakangas, J., Olivera, C., Bishop, J. E., Norman, A. W., and Henry, H. L. (2005) Presence of a truncated form of the vitamin D receptor (VDR) in a strain of VDR-knockout mice. *Endocrinology* **146,** 5581–5586

44. Chia, R., Achilli, F., Festing, M. F., and Fisher, E. M. (2005) The origins and uses of mouse outbred stocks. *Nat. Genet.* **37,** 1181–1186

45. Myers, P., and Armitage, D. (2004) *Rattus norvegicus* (Online), Animal Diversity, Accessed November 20, 2006. http://animaldiversity.ummz.umich.edu/site/accounts/information/Rattus_norvegicus.html

46. Vieth, R., Milojevic, S., and Peltekova, V. (2000) Improved cholecalciferol nutrition in rats is noncalcemic, suppresses parathyroid hormone and increases responsiveness to 1,25-dihydroxycholecalciferol. *J. Nutr.* **130,** 578–584

47. Okano, T., Yasumura, M., Mizuno, K., and Kobayashi, T. (1977) Photochemical conversion of 7-dehydrocholesterol into vitamin D3 in rat skins. *J. Nutr. Sci. Vitaminol. (Tokyo)* **23,** 165–168

48. Eyles, D. W., Smith, S., Kinobe, R., Hewison, M., and McGrath, J. J. (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. *J. Chem. Neuroanat.* **29,** 21–30

49. Naveilhan, P., Berger, F., Haddad, K., Barbot, N., Benabid, A. L., Brachet, P., and Wion, D. (1994) Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors? *J. Neurosci. Res.* **37,** 271–277

50. Vieth, R., and Milojevic, S. (1995) Moderate vitamin D3 supplementation lowers serum 1,25-dihydroxy-vitamin D3 in rats. *Nutr. Res.* **15,** 725–731

51. Liu, P. T., Stenger, S., Li, H., Wenzel, L., Tan, B. H., Krutzik, S. R., Ochoa, M. T., Schauber, J., Wu, K., Meinken, C., Kamen, D. L., Wagner, M., Bals, R., Steinmeyer, A., Zugel, U., Gallo, R. L., Eisenberg, D., Hewison, M., Hollis, B. W., Adams, J. S., Bloom, B. R., and Modlin, R. L. (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* **311,** 1770–1773

52. Gombart, A. F., Borregaard, N., and Koeffler, H. P. (2005) Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly upregulated in myeloid cells by 1,25-dihydroxyvitamin D3. *FASEB J.* **19,** 1067–1077

53. Nehring, J. A., Zierold, C., and DeLuca, H. F. (2007) Lithocholic acid can carry out in vivo functions of vitamin D. *Proc. Natl. Acad. Sci. U. S. A.* **104,** 10006–10009

54. Stumpf, W. E. (2005) Drug localization and targeting with receptor microscopic autoradiography. *J. Pharmacol. Toxicol. Methods* **51,** 25–40

55. Miller, W. L., and Portale, A. A. (2000) Vitamin D 1 alpha-hydroxylase. *Trends Endocrinol. Metab.* **11,** 315–319

56. Zehnder, D., Bland, R., Williams, M. C., McNinch, R. W., Howie, A. J., Stewart, P. M., and Hewison, M. (2001) Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. *J. Clin. Endocrinol. Metab.* **86,** 888–894

57. Luine, V. N., Sonnenberg, J., and Christakos, S. (1987) Vitamin D: is the brain a target? *Steroids* **49,** 133–153

58. Walbert, T., Jirikowski, G. F., and Prufer, K. (2001) Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the limbic system of the rat. *Horm. Metab. Res.* **33,** 525–531

59. Musiol, I. M., Stumpf, W. E., Bidmon, H. J., Heiss, C., Mayerhofer, A., and Bartke, A. (1992) Vitamin D nuclear binding to neurons of the septal, substriatal and amygdaloid area in the Siberian hamster (*Phodopus sungorus*) brain. *Neuroscience* **48,** 841–848

60. Langub, M. C., Herman, J. P., Malluche, H. H., and Koszewski, N. J. (2001) Evidence of functional vitamin D receptors in rat hippocampus. *Neuroscience* **104,** 49–56

61. Taniura, H., Ito, M., Sanada, N., Kuramoto, N., Ohno, Y., Nakamichi, N., and Yoneda, Y. (2006) Chronic vitamin D(3) treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. *J. Neurosci. Res.* **83,** 1179–1189

62. Veenstra, T. D., Prufer, K., Koenigsberger, C., Brimijoin, S. W., Grande, J. P., and Kumar, R. (1998) 1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat embryo. *Brain Res.* **804,** 193–205

63. Johnson, J. A., Grande, J. P., Windebank, A. J., and Kumar, R. (1996) 1,25-Dihydroxyvitamin D(3) receptors in developing dorsal root ganglia of fetal rats. *Brain Res. Dev. Brain Res.* **92,** 120–124

64. Burkert, R., McGrath, J., and Eyles, D. (2003) Vitamin D receptor expression in the embryonic rat brain. *Neurosci. Res. Commun.* **33,** 63–71

65. Prufer, K., Veenstra, T. D., Jirikowski, G. F., and Kumar, R. (1999) Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. *J. Chem. Neuroanat.* **16,** 135–145

66. Baas, D., Prufer, K., Ittel, M. E., Kuchler-Bopp, S., Labourdette, G., Sarlieve, L. L., and Brachet, P. (2000) Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25-dihydroxyvitamin D(3). *Glia* **31,** 59–68

67. Cornet, A., Baudet, C., Neveu, I., Baron-Van Evercooren, A., Brachet, P., and Naveilhan, P. (1998) 1,25-Dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro. *J. Neurosci. Res.* **53,** 742–746

68. Kalueff, A. V., Minasyan, A., Keisala, T., Kuuslahti, M., Miettinen, S., and Tuohimaa, P. (2006) The vitamin D neuroendocrine system as a target for novel neurotropic drugs. *CNS Neurol. Disord. Drug Targets* **5,** 363–371

69. Saporito, M. S., Brown, E. R., Hartpence, K. C., Wilcox, H. M., Vaught, J. L., and Carswell, S. (1994) Chronic 1,25-dihydroxyvi-

tamin D3-mediated induction of nerve growth factor mRNA and protein in L929 fibroblasts and in adult rat brain. *Brain Res.* **633,** 189–196

70. Veenstra, T. D., Londowski, J. M., Windebank, A. J., Brimijoin, S., and Kumar, R. (1997) Effects of 1,25-dihydroxyvitamin D3 on growth of mouse neuroblastoma cells. *Brain Res. Dev. Brain Res.* **99,** 53–60

71. Neveu, I., Naveilhan, P., Jehan, F., Baudet, C., Wion, D., De Luca, H. F., and Brachet, P. (1994) 1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. *Brain Res. Mol. Brain Res.* **24,** 70–76

72. Neveu, I., Naveilhan, P., Baudet, C., Brachet, P., and Metsis, M. (1994) 1,25-dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. *Neuroreport* **6,** 124–126

73. Sanchez, B., Lopez-Martin, E., Segura, C., Labandeira-Garcia, J. L., and Perez-Fernandez, R. (2002) 1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. *Brain Res. Mol. Brain Res.* **108,** 143–146

74. Naveilhan, P., Neveu, I., Wion, D., and Brachet, P. (1996) 1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. *Neuroreport* **7,** 2171–2175

75. Veenstra, T. D., Windebank, A. J., and Kumar, R. (1997) 1,25-dihydroxyvitamin D3 regulates the expression of N-myc, c-myc, protein kinase C, and transforming growth factor-β2 in neuroblastoma cells. *Biochem. Biophys. Res. Commun.* **235,** 15–18

76. Alexianu, M. E., Robbins, E., Carswell, S., and Appel, S. H. (1998) 1α, 25 dihydroxyvitamin D3-dependent up-regulation of calcium-binding proteins in motoneuron cells. *J. Neurosci. Res.* **51,** 58–66

77. Sonnenberg, J., Luine, V. N., Krey, L. C., and Christakos, S. (1986) 1,25-Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. *Endocrinology* **118,** 1433–1439

78. Garcion, E., Sindji, L., Leblondel, G., Brachet, P., and Darcy, F. (1999) 1,25-dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. *J. Neurochem.* **73,** 859–866

79. Prufer, K., and Jirikowski, G. F. (1997) 1.25-Dihydroxyvitamin D3 receptor is partly colocalized with oxytocin immunoreactivity in neurons of the male rat hypothalamus. *Cell. Mol. Biol. (Noisy-le-grand)* **43,** 543–548

80. Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., and Fehr, E. (2005) Oxytocin increases trust in humans. *Nature* **435,** 673–676

81. Insel, T. R., and Young, L. J. (2001) The neurobiology of attachment. *Nat. Rev. Neurosci.* **2,** 129–136

82. Almeras, L., Eyles, D., Benech, P., Laffite, D., Villard, C., Patatian, A., Boucraut, J., Mackay-Sim, A., McGrath, J., and Feron, F. (2007) Developmental vitamin D deficiency alters brain protein expression in the adult rat: Implications for neuropsychiatric disorders. *Proteomics* **7,** 769–780

83. Eyles, D., Brown, J., Mackay-Sim, A., McGrath, J., and Feron, F. (2003) Vitamin D3 and brain development. *Neuroscience* **118,** 641–653

84. Kalueff, A. V., Eremin, K. O., and Tuohimaa, P. (2004) Mechanisms of neuroprotective action of vitamin D3. *Biochemistry (Mosc.)* **69,** 738–741

85. Siegel, G. J., Agranoff, B. W., Albers, R. W., Fisher, S. K., and Uhler, M. D. (1999) *Basic Neurochemistry: Molecular, Cellular and Medical Aspects,* 6th ed., Lippincott, Williams & Wilkins, Philadelphia

86. Woo, N. H., and Lu, B. (2006) Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders. *Neuroscientist* **12,** 43–56

87. Kang, H., and Schuman, E. M. (1995) Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. *Science* **267,** 1658–1662

88. Rose, C. R., Blum, R., Pichler, B., Lepier, A., Kafitz, K. W., and Konnerth, A. (2003) Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells. *Nature* **426,** 74–78

89. Saarma, M., and Sariola, H. (1999) Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF). *Microsc. Res. Tech.* **45,** 292–302

90. Christophersen, N. S., Gronborg, M., Petersen, T. N., Fjord-Larsen, L., Jorgensen, J. R., Juliusson, B., Blom, N., Rosenblad, C., and Brundin, P. (2007) Midbrain expression of delta-like 1

91. homologue is regulated by GDNF and is associated with dopaminergic differentiation. *Exp. Neurol.* **204,** 791–801

92. Schaller, B., Andres, R. H., Huber, A. W., Meyer, M., Perez-Bouza, A., Ducray, A. D., Seiler, R. W., and Widmer, H. R. (2005) Effect of GDNF on differentiation of cultured ventral mesencephalic dopaminergic and non-dopaminergic calretinin-expressing neurons. *Brain Res.* **1036,** 163–172

92. Ledda, F., Paratcha, G., Sandoval-Guzman, T., and Ibanez, C. F. (2007) GDNF and GFRalpha1 promote formation of neuronal synapses by ligand-induced cell adhesion. *Nat. Neurosci.* **10,** 293–300

93. Garcia-Martinez, J. M., Perez-Navarro, E., Gavalda, N., and Alberch, J. (2006) Glial cell line-derived neurotrophic factor promotes the arborization of cultured striatal neurons through the p42/p44 mitogen-activated protein kinase pathway. *J. Neurosci. Res.* **83,** 68–79

94. Do Thi, N. A., Saillour, P., Ferrero, L., Paunio, T., and Mallet, J. (2007) Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease? *Gene Ther.* **14,** 441–450

95. Tomac, A., Lindqvist, E., Lin, L. F., Ogren, S. O., Young, D., Hoffer, B. J., and Olson, L. (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. *Nature* **373,** 335–339

96. Grondin, R., Zhang, Z., Yi, A., Cass, W. A., Maswood, N., Andersen, A. H., Elsberry, D. D., Klein, M. C., Gerhardt, G. A., and Gash, D. M. (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. *Brain* **125,** 2191–2201

97. Sajadi, A., Bensadoun, J. C., Schneider, B. L., Lo Bianco, C., and Aebischer, P. (2006) Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. *Neurobiol. Dis.* **22,** 119–129

98. Stanford, J. A., Salvatore, M. F., Joyce, B. M., Zhang, H., Gash, D. M., and Gerhardt, G. A. (2007) Bilateral effects of unilateral intrastriatal GDNF on locomotor-excited and nonlocomotor-related striatal neurons in aged F344 rats. *Neurobiol. Aging* **28,** 156–165

99. Smith, M. P., and Cass, W. A. (2007) GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease. *Neurosci. Lett.* **412,** 259–263

100. Wang, J. Y., Wu, J. N., Cherng, T. L., Hoffer, B. J., Chen, H. H., Borlongan, C. V., and Wang, Y. (2001) Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. *Brain Res.* **904,** 67–75

101. Smith, M. P., Fletcher-Turner, A., Yurek, D. M., and Cass, W. A. (2006) Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. *Neurochem. Res.* **31,** 533–539

102. Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., and Heywood, P. (2006) Addendum: direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. *Nat. Med.* **12,** 479

103. Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., and Heywood, P. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. *Nat. Med.* **9,** 589–595

104. Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., Brodsky, M. A., Burchiel, K., Kelly, P., Dalvi, A., Scott, B., Stacy, M., Turner, D., Wooten, V. G., Elias, W. J., Laws, E. R., Dhawan, V., Stoessl, A. J., Matcham, J., Coffey, R. J., and Traub, M. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. *Ann. Neurol.* **59,** 459–466

105. Barker, R. A. (2006) Continuing trials of GDNF in Parkinson's disease. *Lancet Neurol.* **5,** 285–286

106. Kotzbauer, P. T., and Holtzman, D. M. (2006) Expectations and challenges in the therapeutic use of neurotrophic factors. *Ann. Neurol.* **59,** 444–447

107. Wang, Y., Chiang, Y. H., Su, T. P., Hayashi, T., Morales, M., Hoffer, B. J., and Lin, S. Z. (2000) Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. *Neuropharmacology* **39,** 873–880

108. Christakos, S., Gabrielides, C., and Rhoten, W. B. (1989) Vitamin D-dependent calcium binding proteins: chemistry, distribution, functional considerations, and molecular biology. *Endocr. Rev.* **10,** 3–26

109. Schwaller, B., Meyer, M., and Schiffmann, S. (2002) 'New' functions for 'old' proteins: the role of the calcium-binding proteins calbindin D-28k, calretinin and parvalbumin, in cerebellar physiology. Studies with knockout mice. *Cerebellum* **1,** 241–258

110. Baimbridge, K. G., Celio, M. R., and Rogers, J. H. (1992) Calcium-binding proteins in the nervous system. *Trends Neurosci.* **15,** 303–308

111. DeViragh, P. A., Haglid, K. G., and Celio, M. R. (1989) Parvalbumin increases in the caudate putamen of rats with vitamin D hypervitaminosis. *Proc. Natl. Acad. Sci. U. S. A.* **86,** 3887–3890

112. Alfahel-Kakunda, A., and Silverman, W. F. (1997) Calcium-binding proteins in the substantia nigra and ventral tegmental area during development: correlation with dopaminergic compartmentalization. *Brain Res. Dev. Brain Res.* **103,** 9–20

113. Ohshima, T., Endo, T., and Onaya, T. (1991) Distribution of parvalbumin immunoreactivity in the human brain. *J. Neurol.* **238,** 320–322

114. Schierle, G. S., Gander, J. C., D'Orlando, C., Ceilo, M. R., and Vogt Weisenhorn, D. M. (1997) Calretinin-immunoreactivity during postnatal development of the rat isocortex: a qualitative and quantitative study. *Cereb. Cortex* **7,** 130–142

115. Ulfig, N. (2002) Calcium-binding proteins in the human developing brain. *Adv. Anat. Embryol. Cell Biol.* **165,** 1–92

116. Kishimoto, J., Tsuchiya, T., Cox, H., Emson, P. C., and Nakayama, Y. (1998) Age-related changes of calbindin-D28k, calretinin, and parvalbumin mRNAs in the hamster brain. *Neurobiol. Aging* **19,** 77–82

117. Heizmann, C. W., and Braun, K. (1992) Changes in Ca(2+)-binding proteins in human neurodegenerative disorders. *Trends Neurosci.* **15,** 259–264

118. Fierro, L., and Llano, I. (1996) High endogenous calcium buffering in Purkinje cells from rat cerebellar slices. *J. Physiol.* **496,** 617–625

119. Pauls, T. L., Cox, J. A., and Berchtold, M. W. (1996) The Ca2+(-)binding proteins parvalbumin and oncomodulin and their genes: new structural and functional findings. *Biochim. Biophys. Acta* **1306,** 39–54

120. Schmidt, H., Schwaller, B., and Eilers, J. (2005) Calbindin D28k targets myo-inositol monophosphatase in spines and dendrites of cerebellar Purkinje neurons. *Proc. Natl. Acad. Sci. U. S. A.* **102,** 5850–5855

121. Berggard, T., Miron, S., Onnerfjord, P., Thulin, E., Akerfeldt, K. S., Enghild, J. J., Akke, M., and Linse, S. (2002) Calbindin D28k exhibits properties characteristic of a Ca^{2+} sensor. *J. Biol. Chem.* **277,** 16662–16672

122. Airaksinen, M. S., Eilers, J., Garaschuk, O., Thoenen, H., Konnerth, A., and Meyer, M. (1997) Ataxia and altered dendritic calcium signaling in mice carrying a targeted null mutation of the calbindin D28k gene. *Proc. Natl. Acad. Sci. U. S. A.* **94,** 1488–1493

123. Chard, P. S., Jordan, J., Marcuccilli, C. J., Miller, R. J., Leiden, J. M., Roos, R. P., and Ghadge, G. D. (1995) Regulation of excitatory transmission at hippocampal synapses by calbindin D28k. *Proc. Natl. Acad. Sci. U. S. A.* **92,** 5144–5148

124. Jouvenceau, A., Potier, B., Poindessous-Jazat, F., Dutar, P., Slama, A., Epelbaum, J., and Billard, J. M. (2002) Decrease in calbindin content significantly alters LTP but not NMDA receptor and calcium channel properties. *Neuropharmacology* **42,** 444–458

125. Molinari, S., Battini, R., Ferrari, S., Pozzi, L., Killcross, A. S., Robbins, T. W., Jouvenceau, A., Billard, J. M., Dutar, P., Lamour, Y., Baker, W. A., Cox, H., and Emson, P. C. (1996) Deficits in memory and hippocampal long-term potentiation in mice with reduced calbindin D28K expression. *Proc. Natl. Acad. Sci. U. S. A.* **93,** 8028–8033

126. Dumas, T. C., Powers, E. C., Tarapore, P. E., and Sapolsky, R. M. (2004) Overexpression of calbindin D(28k) in dentate gyrus granule cells alters mossy fiber presynaptic function and impairs hippocampal-dependent memory. *Hippocampus* **14,** 701–709

127. Westerink, R. H., Rook, M. B., Beekwilder, J. P., and Wadman, W. J. (2006) Dual role of calbindin-D28K in vesicular catecholamine release from mouse chromaffin cells. *J. Neurochem.* **99,** 628–640

128. Barski, J. J., Hartmann, J., Rose, C. R., Hoebeek, F., Morl, K., Noll-Hussong, M., De Zeeuw, C. I., Konnerth, A., and Meyer, M. (2003) Calbindin in cerebellar Purkinje cells is a critical determinant of the precision of motor coordination. *J. Neurosci.* **23,** 3469–3477

129. Toutenhoofd, S. L., and Strehler, E. E. (2000) The calmodulin multigene family as a unique case of genetic redundancy: multiple levels of regulation to provide spatial and temporal control of calmodulin pools? *Cell Calcium* **28,** 83–96

130. DeBoland, A. R., Massheimer, V., and Fernandez, L. M. (1988) 1,25 Dihydroxyvitamin D3 affects calmodulin distribution among subcellular fractions of skeletal muscle. *Calcif. Tissue Int.* **43,** 370–375

131. Vazquez, G., de Boland, A. R., and Boland, R. L. (2000) Involvement of calmodulin in 1α,25-dihydroxyvitamin D3 stimulation of store-operated Ca^{2+} influx in skeletal muscle cells. *J. Biol. Chem.* **275,** 16134–16138

132. Gnegy, M. E. (1993) Calmodulin in neurotransmitter and hormone action. *Annu. Rev. Pharmacol. Toxicol.* **33,** 45–70

133. Gnegy, M. E. (2000) Ca^{2+}/calmodulin signaling in NMDA-induced synaptic plasticity. *Crit. Rev. Neurobiol.* **14,** 91–129

134. Junge, H. J., Rhee, J. S., Jahn, O., Varoqueaux, F., Spiess, J., Waxham, M. N., Rosenmund, C., and Brose, N. (2004) Calmodulin and Munc13 form a Ca^{2+} sensor/effector complex that controls short-term synaptic plasticity. *Cell* **118,** 389–401

135. Lisman, J., Schulman, H., and Cline, H. (2002) The molecular basis of CaMKII function in synaptic and behavioural memory. *Nat. Rev. Neurosci.* **3,** 175–190

136. Mizuno, K., Antunes-Martins, A., Ris, L., Peters, M., Godaux, E., and Giese, K. P. (2007) Calcium/calmodulin kinase kinase beta has a male-specific role in memory formation. *Neuroscience* **145,** 393–402

137. Poulsen, D. J., Standing, D., Bullshields, K., Spencer, K., Micevych, P. E., and Babcock, A. M. (2007) Overexpression of hippocampal Ca^{2+}/calmodulin-dependent protein kinase II improves spatial memory. *J. Neurosci. Res.* **85,** 735–739

138. Yamauchi, T. (2005) Neuronal Ca^{2+}/calmodulin-dependent protein kinase II–discovery, progress in a quarter of a century, and perspective: implication for learning and memory. *Biol. Pharm. Bull.* **28,** 1342–1354

139. Bergh, J. J., Shao, Y., Puente, E., Duncan, R. L., and Farach-Carson, M. C. (2006) Osteoblast Ca^{2+} permeability and voltage-sensitive Ca^{2+} channel expression is temporally regulated by 1,25-dihydroxyvitamin D3. *Am. J. Physiol. Cell Physiol.* **290,** C822–C831

140. Takeuchi, K., and Guggino, S. E. (1996) 24R,25-(OH)2 vitamin D3 inhibits 1alpha,25-(OH)2 vitamin D3 and testosterone potentiation of calcium channels in osteosarcoma cells. *J. Biol. Chem.* **271,** 33335–33343

141. Brewer, L. D., Porter, N. M., Kerr, D. S., Landfield, P. W., and Thibault, O. (2006) Chronic 1α,25-(OH)(2)vitamin D3 treatment reduces Ca^{2+}-mediated hippocampal biomarkers of aging. *Cell Calcium* 40: 277–286

142. Berridge, M. J. (1998) Neuronal calcium signaling. *Neuron* **21,** 13–26

143. Demaurex, N., and Distelhorst, C. (2003) Cell biology. Apoptosis—the calcium connection. *Science* **300,** 65–67

144. Berridge, M. J. (2004) Calcium signal transduction and cellular control mechanisms. *Biochim. Biophys. Acta* **1742,** 3–7

145. Berridge, M. J. (2006) Calcium microdomains: organization and function. *Cell Calcium* **40,** 405–412

146. Leclerc, C., Neant, I., Webb, S. E., Miller, A. L., and Moreau, M. (2006) Calcium transients and calcium signalling during early neurogenesis in the amphibian embryo *Xenopus laevis*. *Biochim. Biophys. Acta* **1763,** 1184–1191

147. Komuro, H., and Rakic, P. (1996) Intracellular Ca^{2+} fluctuations modulate the rate of neuronal migration. *Neuron* **17,** 275–285

148. Brewer, L. D., Thibault, V., Chen, K. C., Langub, M. C., Landfield, P. W., and Porter, N. M. (2001) Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. *J. Neurosci.* **21,** 98–108

149. Halloran, B. P. (1994) Cellular growth and differentiation during embryogenesis and fetal development. The role of vitamin D. *Adv. Exp. Med. Biol.* **352,** 227–236

150. Bikle, D. D. (2004) Vitamin D regulated keratinocyte differentiation. *J. Cell. Biochem.* **92,** 436–444

151. VanDriel, M., Pols, H. A., and van Leeuwen, J. P. (2004) Osteoblast differentiation and control by vitamin D and vitamin D metabolites. *Curr. Pharm. Des.* **10,** 2535–2555

152. Moore, T. B., Koeffler, H. P., Yamashiro, J. M., and Wada, R. K. (1996) Vitamin D3 analogs inhibit growth and induce differentiation in LA-N-5 human neuroblastoma cells. *Clin. Exp. Metastasis* **14,** 239–245

153. Stio, M., Celli, A., and Treves, C. (2001) Synergistic antiproliferative effects of vitamin D derivatives and 9-cis retinoic acid in SH-SY5Y human neuroblastoma cells. *J. Steroid. Biochem. Mol. Biol.* **77,** 213–222

154. Goplen, D. P., Brackman, D., and Aksnes, L. (1994) Effects of 1,25-dihydroxyvitamin D3 and retinoic acid on the proliferation and cell cycle phase distribution of neuroblastoma SK-N-SH cells. *Pediatr. Hematol. Oncol.* **11,** 173–179

155. Brown, J., Bianco, J. I., McGrath, J. J., and Eyles, D. W. (2003) 1,25-dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. *Neurosci. Lett.* **343,** 139–143

156. Obradovic, D., Gronemeyer, H., Lutz, B., and Rein, T. (2006) Cross-talk of vitamin D and glucocorticoids in hippocampal cells. *J. Neurochem.* **96,** 500–509

157. Choi, W. S., Chun, S. Y., Markelonis, G. J., Oh, T. H., and Oh, Y. J. (2001) Overexpression of calbindin-D28K induces neurite outgrowth in dopaminergic neuronal cells via activation of p38 MAPK. *Biochem. Biophys. Res. Commun.* **287,** 656–661

158. Kim, J. H., Lee, J. A., Song, Y. M., Park, C. H., Hwang, S. J., Kim, Y. S., Kaang, B. K., and Son, H. (2006) Overexpression of calbindin-D28K in hippocampal progenitor cells increases neuronal differentiation and neurite outgrowth. *FASEB J.* **20,** 109–111

159. Lledo, P. M., Alonso, M., and Grubb, M. S. (2006) Adult neurogenesis and functional plasticity in neuronal circuits. *Nat. Rev. Neurosci.* **7,** 179–193

160. Hagg, T. (2005) Molecular regulation of adult CNS neurogenesis: an integrated view. *Trends Neurosci.* **28,** 589–595

161. Watts, C., McConkey, H., Anderson, L., and Caldwell, M. (2005) Anatomical perspectives on adult neural stem cells. *J. Anat.* **207,** 197–208

162. Taupin, P., and Gage, F. H. (2002) Adult neurogenesis and neural stem cells of the central nervous system in mammals. *J. Neurosci. Res.* **69,** 745–749

163. Purves, D., Fitzpatrick, D., Augustine, G. J., Katz, L. C., Williams, S. M., McNamara, J. O., and Lamantia, A.-S. (2001) *Neuroscience,* 2nd ed., Sinaur Associates, Sunderland, Massachusetts, USA

164. Cianferotti, L., Cox, M., Skorija, K., and Demay, M. B. (2007) Vitamin D receptor is essential for normal keratinocyte stem cell function. *Proc. Natl. Acad. Sci. U. S. A.* **104,** 9428–9433

165. Cui, X., McGrath, J. J., Burne, T. H., Mackay-Sim, A., and Eyles, D. W. (2007) Maternal vitamin D depletion alters neurogenesis in the developing rat brain. *Int. J. Dev. Neurosci.* **25,** 227–232

166. Landfield, P. W., and Cadwallader-Neal, L. (1998) Long-term treatment with calcitriol (1,25(OH)2 vit D3) retards a biomarker of hippocampal aging in rats. *Neurobiol. Aging* **19,** 469–477

167. McGrath, J. J., Feron, F. P., Burne, T. H., Mackay-Sim, A., and Eyles, D. W. (2004) Vitamin D3-implications for brain development. *J. Steroid Biochem. Mol. Biol.* **89-90,** 557–560

168. Ko, P., Burkert, R., McGrath, J., and Eyles, D. (2004) Maternal vitamin D3 deprivation and the regulation of apoptosis and cell cycle during rat brain development. *Brain Res. Dev. Brain Res.* **153,** 61–68

169. Feron, F., Burne, T. H., Brown, J., Smith, E., McGrath, J. J., Mackay-Sim, A., and Eyles, D. W. (2005) Developmental vitamin D3 deficiency alters the adult rat brain. *Brain Res. Bull.* **65,** 141–148

170. Stio, M., Lunghi, B., Iantomasi, T., Vincenzini, M. T., and Treves, C. (1993) Effect of vitamin D deficiency and 1,25-dihydroxyvitamin D3 on metabolism and D-glucose transport in rat cerebral cortex. *J. Neurosci. Res.* **35,** 559–566

171. Harris, R. A., Carnes, D. L., and Forte, L. R. (1981) Reduction of brain calcium after consumption of diets deficient in calcium or vitamin D. *J. Neurochem.* **36,** 460–466

172. McGrath, J. (1999) Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia? *Schizophr. Res.* **40,** 173–177

173. Mackay-Sim, A., Feron, F., Eyles, D., Burne, T., and McGrath, J. (2004) Schizophrenia, vitamin D, and brain development. *Int. Rev. Neurobiol.* **59,** 351–380

174. McGrath, J. J., Saha, S., Lieberman, D. E., and Buka, S. (2006) Season of birth is associated with anthropometric and neuro-cognitive outcomes during infancy and childhood in a general population birth cohort. *Schizophr. Res.* **81,** 91–100

175. Davies, G., Welham, J., Chant, D., Torrey, E. F., and McGrath, J. (2003) A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. *Schizophr. Bull.* **29,** 587–593

176. Saha, S., Chant, D. C., Welham, J. L., and McGrath, J. J. (2006) The incidence and prevalence of schizophrenia varies with latitude. *Acta Psychiatr. Scand.* **114,** 36–39

177. Harrison, P. J. (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. *Brain* **122,** 593–624

178. McGrath, J., Eyles, D., Mowry, B., Yolken, R., and Buka, S. (2003) Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. *Schizophr. Res.* **63,** 73–78

179. McGrath, J., Saari, K., Hakko, H., Jokelainen, J., Jones, P., Jarvelin, M. R., Chant, D., and Isohanni, M. (2004) Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. *Schizophr. Res.* **67,** 237–245

180. Yan, J., Feng, J., Craddock, N., Jones, I. R., Cook, E. H., Jr., Goldman, D., Heston, L. L., Chen, J., Burkhart, P., Li, W., Shibayama, A., and Sommer, S. S. (2005) Vitamin D receptor variants in 192 patients with schizophrenia and other psychiatric diseases. *Neurosci. Lett.* **380,** 37–41

181. Handoko, H. Y., Nancarrow, D. J., Mowry, B. J., and McGrath, J. J. (2006) Polymorphisms in the vitamin D receptor and their associations with risk of schizophrenia and selected anthropometric measures. *Am. J. Hum. Biol.* **18,** 415–417

182. Ozer, S., Ulusahin, A., Ulusoy, S., Okur, H., Coskun, T., Tuncali, T., Gogus, A., and Akarsu, A. N. (2004) Is vitamin D hypothesis for schizophrenia valid? Independent segregation of psychosis in a family with vitamin-D-dependent rickets type IIA. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **28,** 255–266

183. Stumpf, W. E., and Privette, T. H. (1989) Light, vitamin D and psychiatry. Role of 1,25 dihydroxyvitamin D3 (soltriol) in etiology and therapy of seasonal affective disorder and other mental processes. *Psychopharmacology (Berl.)* **97,** 285–294

184. Winkler, D., Pjrek, E., Iwaki, R., and Kasper, S. (2006) Treatment of seasonal affective disorder. *Expert Rev. Neurother.* **6,** 1039–1048

185. Lewy, A. J., Lefler, B. J., Emens, J. S., and Bauer, V. K. (2006) The circadian basis of winter depression. *Proc. Natl. Acad. Sci. U. S. A.* **103,** 7414–7419

186. Danilenko, K. V., Putilov, A. A., Russkikh, G. S., Duffy, L. K., and Ebbesson, S. O. (1994) Diurnal and seasonal variations of melatonin and serotonin in women with seasonal affective disorder. *Arctic Med. Res.* **53,** 137–145

187. Srinivasan, V., Smits, M., Spence, W., Lowe, A. D., Kayumov, L., Pandi-Perumal, S. R., Parry, B., and Cardinali, D. P. (2006) Melatonin in mood disorders. *World J. Biol. Psychiatry* **7,** 138–151

188. Gloth, F. M., 3rd, Alam, W., and Hollis, B. (1999) Vitamin D vs. broad spectrum phototherapy in the treatment of seasonal affective disorder. *J. Nutr. Health Aging* **3,** 5–7

189. Vieth, R., Kimball, S., Hu, A., and Walfish, P. G. (2004) Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the well being of patients. *Nutr. J.* **3,** 8

190. Lansdowne, A. T., and Provost, S. C. (1998) Vitamin D3 enhances mood in healthy subjects during winter. *Psychopharmacology (Berl.)* **135,** 319–323

191. Dumville, J. C., Miles, J. N., Porthouse, J., Cockayne, S., Saxon, L., and King, C. (2006) Can vitamin D supplementation prevent winter-time blues? A randomised trial among older women. *J. Nutr. Health Aging* **10,** 151–153

192. Kenny, A. M., Biskup, B., Robbins, B., Marcella, G., and Burleson, J. A. (2003) Effects of vitamin D supplementation on strength, physical function, and health perception in older, community-dwelling men. *J. Am. Geriatr. Soc.* **51,** 1762–1767

193. Wilkins, C. H., Sheline, Y. I., Roe, C. M., Birge, S. J., and Morris, J. C. (2006) Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. *Am. J. Geriatr. Psychiatry* **14,** 1032–1040

194. Kuningas, M., Mooijaart, S. P., Jolles, J., Slagboom, P. E., Westendorp, R. G., and van Heemst, D. (2007) VDR gene variants associate with cognitive function and depressive symptoms in old age. *Neurobiol. Aging.* In press.

195. Gezen-Ak, D., Dursun, E., Ertan, T., Hanagasi, H., Gurvit, H., Emre, M., Eker, E., Ozturk, M., Engin, F., and Yilmazer, S. (2007) Association between vitamin D receptor gene polymorphism and Alzheimer's disease. *Tohoku J. Exp. Med.* **212,** 275–282

196. Przybelski, R. J., and Binkley, N. C. (2007) Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. *Arch. Biochem. Biophys.* **460,** 202–205

197. Becker, A., Eyles, D. W., McGrath, J. J., and Grecksch, G. (2005) Transient prenatal vitamin D deficiency is associated with subtle alterations in learning and memory functions in adult rats. *Behav. Brain Res.* **161,** 306–312

198. Becker, A., and Grecksch, G. (2006) Pharmacological treatment to augment hole board habituation in prenatal Vitamin D-deficient rats. *Behav. Brain Res.* **166,** 177–183

199. Burne, T. H., Becker, A., Brown, J., Eyles, D. W., Mackay-Sim, A., and McGrath, J. J. (2004) Transient prenatal vitamin D deficiency is associated with hyperlocomotion in adult rats. *Behav. Brain Res.* **154,** 549–555

200. Burne, T. H., Feron, F., Brown, J., Eyles, D. W., McGrath, J. J., and Mackay-Sim, A. (2004) Combined prenatal and chronic postnatal vitamin D deficiency in rats impairs prepulse inhibition of acoustic startle. *Physiol. Behav.* **81,** 651–655

201. Eyles, D. W., Rogers, F., Buller, K., McGrath, J. J., Ko, P., French, K., and Burne, T. H. (2006) Developmental vitamin D (DVD) deficiency in the rat alters adult behaviour independently of HPA function. *Psychoneuroendocrinology* **31,** 958–964

202. Kesby, J. P., Burne, T. H., McGrath, J. J., and Eyles, D. W. (2006) Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: an animal model of schizophrenia. *Biol. Psychiatry* **60,** 591–596

203. O'Loan, J., Eyles, D. W., Kesby, J., Ko, P., McGrath, J. J., and Burne, T. H. (2007) Vitamin D deficiency during various stages of pregnancy in the rat; its impact on development and behaviour in adult offspring. *Psychoneuroendocrinology* **32,** 227–234

204. Burne, T. H., McGrath, J. J., Eyles, D. W., and Mackay-Sim, A. (2005) Behavioural characterization of vitamin D receptor knockout mice. *Behav. Brain Res.* **157,** 299–308

205. Kalueff, A. V., Lou, Y. R., Laaksi, I., and Tuohimaa, P. (2004) Increased anxiety in mice lacking vitamin D receptor gene. *Neuroreport* **15,** 1271–1274

206. Kalueff, A. V., Keisala, T., Minasyan, A., Kuuslahti, M., Miettinen, S., and Tuohimaa, P. (2006) Behavioural anomalies in mice evoked by "Tokyo" disruption of the vitamin D receptor gene. *Neurosci. Res.* **54,** 254–260

207. Kalueff, A. V., Lou, Y. R., Laaksi, I., and Tuohimaa, P. (2004) Impaired motor performance in mice lacking neurosteroid vitamin D receptors. *Brain Res. Bull.* **64,** 25–29

208. Kalueff, A. V., Lou, Y. R., Laaksi, I., and Tuohimaa, P. (2004) Increased grooming behavior in mice lacking vitamin D receptors. *Physiol. Behav.* **82,** 405–409

209. Kalueff, A. V., Lou, Y. R., Laaksi, I., and Tuohimaa, P. (2005) Abnormal behavioral organization of grooming in mice lacking the vitamin D receptor gene. *J. Neurogenet.* **19,** 1–24

210. Keisala, T., Minasyan, A., Jarvelin, U., Wang, J., Hamalainen, T., Kalueff, A. V., and Tuohimaa, P. (2007) Aberrant nest building and prolactin secretion in vitamin D receptor mutant mice. *J. Steroid Biochem. Mol. Biol.* **104,** 269–273

211. Burne, T. H., Johnston, A. N., McGrath, J. J., and Mackay-Sim, A. (2006) Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice. *Brain Res. Bull.* **69,** 74–78

212. Minasyan, A., Keisala, T., Lou, Y. R., Kalueff, A. V., and Tuohimaa, P. (2007) Neophobia, sensory and cognitive functions, and hedonic responses in vitamin D receptor mutant mice. *J. Steroid Biochem. Mol. Biol.* **104,** 274–280

213. Li, Y. C., Pirro, A. E., Amling, M., Delling, G., Baron, R., Bronson, R., and Demay, M. B. (1997) Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. *Proc. Natl. Acad. Sci. U. S. A.* **94,** 9831–9835

214. Kalueff, A., Loseva, E., Haapasalo, H., Rantala, I., Keranen, J., Lou, Y. R., Minasyan, A., Keisala, T., Miettinen, S., Kuuslahti, M., and Tuohimaa, P. (2006) Thalamic calcification in vitamin D receptor knockout mice. *Neuroreport* **17,** 717–721

215. Li, Y. C., Amling, M., Pirro, A. E., Priemel, M., Meuse, J., Baron, R., Delling, G., and Demay, M. B. (1998) Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. *Endocrinology* **139,** 4391–4396

216. Altemus, K. L., Finger, S., Wolf, C., and Birge, S. J. (1987) Behavioral correlates of vitamin D deficiency. *Physiol. Behav.* **39,** 435–440

217. Hill, A. (1971) *Principles of Medical Statistics,* 9th ed., Oxford University Press, New York

218. Holick, M. F. (2006) Resurrection of vitamin D deficiency and rickets. *J. Clin. Invest.* **116,** 2062–2072

219. Raison, C. L., Capuron, L., and Miller, A. H. (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. *Trends Immunol.* **27,** 24–31

220. Gold, S. M., and Irwin, M. R. (2006) Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. *Neurol. Clin.* **24,** 507–519

221. Sheehy, C., Murphy, E., and Barry, M. (2006) Depression in rheumatoid arthritis–underscoring the problem. *Rheumatology (Oxford)* **45,** 1325–1327

222. Anisman, H., Merali, Z., Poulter, M. O., and Hayley, S. (2005) Cytokines as a precipitant of depressive illness: animal and human studies. *Curr. Pharm. Des.* **11,** 963–972

223. Pucak, M. L., and Kaplin, A. I. (2005) Unkind cytokines: current evidence for the potential role of cytokines in immune-mediated depression. *Int. Rev. Psychiatry* **17,** 477–483

224. Schiepers, O. J., Wichers, M. C., and Maes, M. (2005) Cytokines and major depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **29,** 201–217

225. O'Connor, J. C., Johnson, D. R., and Freund, G. G. (2006) Psychoneuroimmune implications of type 2 diabetes. *Neurol. Clin.* **24,** 539–559

226. Saykin, A. J., Ahles, T. A., and McDonald, B. C. (2003) Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. *Semin. Clin. Neuropsychiatry* **8,** 201–216

227. Ferguson, R. J., and Ahles, T. A. (2003) Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. *Curr. Neurol. Neurosci. Rep.* **3,** 215–222

228. Black, P. H. (2006) The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II. *Med. Hypotheses* **67,** 879–891

229. Wilson, C. J., Finch, C. E., and Cohen, H. J. (2002) Cytokines and cognition—the case for a head-to-toe inflammatory paradigm. *J. Am. Geriatr. Soc.* **50,** 2041–2056

230. Dunn, A. J., Swiergiel, A. H., and de Beaurepaire, R. (2005) Cytokines as mediators of depression: what can we learn from animal studies? *Neurosci. Biobehav. Rev.* **29,** 891–909

231. Watkins, L. R., and Maier, S. F. (2005) Immune regulation of central nervous system functions: from sickness responses to pathological pain. *J. Intern. Med.* **257,** 139–155

232. Dantzer, R. (2006) Cytokine, sickness behavior, and depression. *Neurol. Clin.* **24,** 441–460

233. Miller, D. B., and O'Callaghan, J. P. (2005) Depression, cytokines, and glial function. *Metabolism* **54,** 33–38

234. DeBeaurepaire, R. (2002) Questions raised by the cytokine hypothesis of depression. *Brain Behav. Immun.* **16,** 610–617

235. O'Shea, J. J., Ma, A., and Lipsky, P. (2002) Cytokines and autoimmunity. *Nat. Rev. Immunol.* **2,** 37–45

236. Dinarello, C. A. (2000) Proinflammatory cytokines. *Chest* **118,** 503–508

237. Smith, R. S. (1991) The macrophage theory of depression. *Med. Hypotheses* **35,** 298–306

238. Pugh, C. R., Nguyen, K. T., Gonyea, J. L., Fleshner, M., Wakins, L. R., Maier, S. F., and Rudy, J. W. (1999) Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. *Behav. Brain Res.* **106,** 109–118

239. Matsumoto, Y., Yamaguchi, T., Watanabe, S., and Yamamoto, T. (2004) Involvement of arachidonic acid cascade in working memory impairment induced by interleukin-1 beta. *Neuropharmacology* **46,** 1195–1200

240. Matsumoto, Y., Yoshida, M., Watanabe, S., and Yamamoto, T. (2001) Involvement of cholinergic and glutamatergic functions in working memory impairment induced by interleukin-1beta in rats. *Eur. J. Pharmacol.* **430,** 283–288

241. Palin, K., Bluthe, R. M., Verrier, D., Tridon, V., Dantzer, R., and Lestage, J. (2004) Interleukin-1beta mediates the memory impairment associated with a delayed type hypersensitivity response to bacillus Calmette-Guerin in the rat hippocampus. *Brain Behav. Immun.* **18,** 223–230

242. Griffin, M. D., Xing, N., and Kumar, R. (2003) Vitamin D and its analogs as regulators of immune activation and antigen presentation. *Annu. Rev. Nutr.* **23,** 117–145

243. Baeke, F., VanEtten, E., Overbergh, L., and Mathieu, C. (2007) Vitamin D3 and the immune system: maintaining the balance in health and disease. *Nutr. Res. Rev.* **20,** 106–118

244. Adorini, L., Penna, G., Giarratana, N., Roncari, A., Amuchastegui, S., Daniel, K. C., and Uskokovic, M. (2004) Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. *J. Steroid Biochem. Mol. Biol.* **89-90,** 437–441

245. Muller, K., Haahr, P. M., Diamant, M., Rieneck, K., Kharazmi, A., and Bendtzen, K. (1992) 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. *Cytokine* **4,** 506–512

246. D'Ambrosio, D., Cippitelli, M., Cocciolo, M. G., Mazzeo, D., Di Lucia, P., Lang, R., Sinigaglia, F., and Panina-Bordignon, P. (1998) Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. *J. Clin. Invest.* **101,** 252–262

247. Stio, M., Treves, C., Martinesi, M., and Bonanomi, A. G. (2005) Biochemical effects of KH 1060 and anti-TNF monoclonal antibody on human peripheral blood mononuclear cells. *Int. Immunopharmacol.* **5,** 649–659

248. Lefebvre d'Hellencourt, C., Montero-Menei, C. N., Bernard, R., and Couez, D. (2003) Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production by the EOC13 microglial cell line. *J. Neurosci. Res.* **71,** 575–582

249. Kong, J., Grando, S. A., and Li, Y. C. (2006) Regulation of IL-1 family cytokines IL-1alpha, IL-1 receptor antagonist, and IL-18 by 1,25-dihydroxyvitamin D3 in primary keratinocytes. *J. Immunol.* **176,** 3780–3787

250. Gurlek, A., Pittelkow, M. R., and Kumar, R. (2002) Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. *Endocr. Rev.* **23,** 763–786

251. Equils, O., Naiki, Y., Shapiro, A. M., Michelsen, K., Lu, D., Adams, J., and Jordan, S. (2006) 1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. *Clin. Exp. Immunol.* **143,** 58–64

252. Adorini, L., Penna, G., Amuchastegui, S., Cossetti, C., Aquilano, F., Mariani, R., Fibbi, B., Morelli, A., Uskokovic, M., Colli, E., and Maggi, M. (2007) Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). *J. Steroid Biochem. Mol. Biol.* **103,** 689–693

253. Schleithoff, S. S., Zittermann, A., Tenderich, G., Berthold, H. K., Stehle, P., and Koerfer, R. (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. *Am. J. Clin. Nutr.* **83,** 754–759

254. Zhu, Y., Mahon, B. D., Froicu, M., and Cantorna, M. T. (2005) Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. *Eur. J. Immunol.* **35,** 217–224

255. Froicu, M., and Cantorna, M. T. (2007) Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. *BMC Immunol.* **8,** 5

256. Timms, P. M., Mannan, N., Hitman, G. A., Noonan, K., Mills, P. G., Syndercombe-Court, D., Aganna, E., Price, C. P., and Boucher, B. J. (2002) Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? *QJM* **95,** 787–796

257. Zittermann, A., Dembinski, J., and Stehle, P. (2004) Low vitamin D status is associated with low cord blood levels of the immunosuppressive cytokine interleukin-10. *Pediatr. Allergy. Immunol.* **15,** 242–246

258. Sun, J., Kong, J., Duan, Y., Szeto, F. L., Liao, A., Madara, J. L., and Li, Y. C. (2006) Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. *Am. J. Physiol. Endocrinol. Metab.* **291,** E315–322

259. Nadjar, A., Bluthe, R. M., May, M. J., Dantzer, R., and Parnet, P. (2005) Inactivation of the cerebral NFkappaB pathway inhibits interleukin-1beta-induced sickness behavior and c-Fos expression in various brain nuclei. *Neuropsychopharmacology* **30,** 1492–1499

260. Bierhaus, A., Wolf, J., Andrassy, M., Rohleder, N., Humpert, P. M., Petrov, D., Ferstl, R., von Eynatten, M., Wendt, T., Rudofsky, G., Joswig, M., Morcos, M., Schwaninger, M., McEwen, B., Kirschbaum, C., and Nawroth, P. P. (2003) A mechanism converting psychosocial stress into mononuclear cell activation. *Proc. Natl. Acad. Sci. U. S. A.* **100,** 1920–1925

261. Madrigal, J. L., Hurtado, O., Moro, M. A., Lizasoain, I., Lorenzo, P., Castrillo, A., Bosca, L., and Leza, J. C. (2002) The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. *Neuropsychopharmacology* **26,** 155–163

262. Maier, S. F. (2003) Bi-directional immune-brain communication: Implications for understanding stress, pain, and cognition. *Brain Behav. Immun.* **17,** 69–85

263. Buller, K. M. (2001) Role of circumventricular organs in pro-inflammatory cytokine-induced activation of the hypothalamic-pituitary-adrenal axis. *Clin. Exp. Pharmacol. Physiol.* **28,** 581–589

264. Neveu, I., Naveilhan, P., Menaa, C., Wion, D., Brachet, P., and Garabedian, M. (1994) Synthesis of 1,25-dihydroxyvitamin D3 by rat brain macrophages in vitro. *J. Neurosci. Res.* **38,** 214–220

265. Hauwel, M., Furon, E., Canova, C., Griffiths, M., Neal, J., and Gasque, P. (2005) Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, "protective" glial stem cells and stromal ependymal cells. *Brain Res. Brain Res. Rev.* **48,** 220–233

266. Kim, Y. S., and Joh, T. H. (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. *Exp. Mol. Med.* **38,** 333–347

267. Dheen, S. T., Kaur, C., and Ling, E. A. (2007) Microglial activation and its implications in the brain diseases. *Curr. Med. Chem.* **14,** 1189–1197

268. Moore, M. E., Piazza, A., McCartney, Y., and Lynch, M. A. (2005) Evidence that vitamin D3 reverses age-related inflammatory changes in the rat hippocampus. *Biochem. Soc. Trans.* **33,** 573–577

269. Armstrong, D. J., Meenagh, G. K., Bickle, I., Lee, A. S., Curran, E. S., and Finch, M. B. (2007) Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. *Clin. Rheumatol.* **26,** 551–554

270. Cantorna, M. T. (2006) Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. *Prog. Biophys. Mol. Biol.* **92,** 60–64

271. Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., and Ascherio, A. (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *JAMA* **296,** 2832–2838

272. Kantarci, O., and Wingerchuk, D. (2006) Epidemiology and natural history of multiple sclerosis: new insights. *Curr. Opin. Neurol.* **19,** 248–254

273. McGrath, J. (2001) Does 'imprinting' with low prenatal vitamin D contribute to the risk of various adult disorders? *Med. Hypotheses* **56,** 367–371

274. Mathieu, C., and Badenhoop, K. (2005) Vitamin D and type 1 diabetes mellitus: state of the art. *Trends Endocrinol. Metab.* **16,** 261–266

275. Holick, M. F. (2005) The vitamin D epidemic and its health consequences. *J. Nutr.* **135,** 2739S–2748S

276. Pappa, H. M., Gordon, C. M., Saslowsky, T. M., Zholudev, A., Horr, B., Shih, M. C., and Grand, R. J. (2006) Vitamin D status

in children and young adults with inflammatory bowel disease. *Pediatrics* **118,** 1950–1961

277. Koutkia, P., Lu, Z., Chen, T. C., and Holick, M. F. (2001) Treatment of vitamin D deficiency due to Crohn's disease with tanning bed ultraviolet B radiation. *Gastroenterology* **121,** 1485–1488

278. Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., and Holick, M. F. (2000) Decreased bioavailability of vitamin D in obesity. *Am. J. Clin. Nutr.* **72,** 690–693

279. Martini, L. A., and Wood, R. J. (2006) Vitamin D status and the metabolic syndrome. *Nutr. Rev.* **64,** 479–486

280. Pittas, A. G., Lau, J., Hu, F. B., and Dawson-Hughes, B. (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *J. Clin. Endocrinol. Metab.* **92,** 2017–2029

281. Mathieu, C., Gysemans, C., Giulietti, A., and Bouillon, R. (2005) Vitamin D and diabetes. *Diabetologia* **48,** 1247–1257

282. Miller, E. H. (2006) Vitamin D insufficiency in male osteoporosis. *Clin. Cornerstone* **8**(Suppl 3), S14–S19

283. Lips, P., Hosking, D., Lippuner, K., Norquist, J. M., Wehren, L., Maalouf, G., Ragi-Eis, S., and Chandler, J. (2006) The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. *J. Intern. Med.* **260,** 245–254

284. Duque, G., Macoritto, M., Dion, N., Ste-Marie, L. G., and Kremer, R. (2005) 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). *Am. J. Physiol. Endocrinol. Metab.* **288,** E723–E730

285. Grant, W. B. (2006) Epidemiology of disease risks in relation to vitamin D insufficiency. *Prog. Biophys. Mol. Biol.* **92,** 65–79

286. Zittermann, A. (2006) Vitamin D and disease prevention with special reference to cardiovascular disease. *Prog. Biophys. Mol. Biol.* **92,** 39–48

287. Luong, K. V., and Nguyen, L. T. (2006) Vitamin D and cardiovascular disease. *Curr. Med. Chem.* **13,** 2443–2447

288. Martineau, A. R., Wilkinson, R. J., Wilkinson, K. A., Newton, S. M., Kampmann, B., Hall, B. M., Packe, G. E., Davidson, R. N., Eldridge, S. M., Maunsell, Z. J., Rainbow, S. J., Berry, J. L., and Griffiths, C. J. (2007) A single dose of vitamin D enhances immunity to mycobacteria. *Am. J. Respir. Crit. Care Med.* **176,** 208–213

289. Cannell, J. J., Vieth, R., Umhau, J. C., Holick, M. F., Grant, W. B., Madronich, S., Garland, C. F., and Giovannucci, E. (2006) Epidemic influenza and vitamin D. *Epidemiol. Infect.* **134,** 1129–1140

290. Newmark, H. L., and Newmark, J. (2007) Vitamin D and Parkinson's disease—a hypothesis. *Mov. Disord.* **22,** 461–468

291. Kim, J. S., Kim, Y. I., Song, C., Yoon, I., Park, J. W., Choi, Y. B., Kim, H. T., and Lee, K. S. (2005) Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans. *J. Korean Med. Sci.* **20,** 495–498

292. Sato, Y., Asoh, T., and Oizumi, K. (1998) High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. *Bone* **23,** 555–557

293. Sato, Y., Iwamoto, J., Kanoko, T., and Satoh, K. (2005) Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: a randomized controlled trial. *J. Bone Miner. Res.* **20,** 1327–1333

294. Amato, M. P., Zipoli, V., and Portaccio, E. (2006) Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. *J. Neurol. Sci.* **245,** 41–46

295. Wallin, M. T., Wilken, J. A., and Kane, R. (2006) Cognitive dysfunction in multiple sclerosis: Assessment, imaging, and risk factors. *J. Rehabil. Res. Dev.* **43,** 63–72

296. Jonsson, A., Andresen, J., Storr, L., Tscherning, T., Soelberg Sorensen, P., and Ravnborg, M. (2006) Cognitive impairment in newly diagnosed multiple sclerosis patients: a 4-year follow-up study. *J. Neurol. Sci.* **245,** 77–85

297. Arnett, P. A., and Randolph, J. J. (2006) Longitudinal course of depression symptoms in multiple sclerosis. *J. Neurol. Neurosurg. Psychiatry* **77,** 606–610

298. Barnard, K. D., Skinner, T. C., and Peveler, R. (2006) The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. *Diabet. Med.* **23,** 445–448

299. Brands, A. M., Kessels, R. P., Hoogma, R. P., Henselmans, J. M., van der Beek Boter, J. W., Kappelle, L. J., de Haan, E. H., and Biessels, G. J. (2006) Cognitive performance, psychological well-being, and brain magnetic resonance imaging in older patients with type 1 diabetes. *Diabetes* **55,** 1800–1806

300. Ryan, C. M. (2006) Why is cognitive dysfunction associated with the development of diabetes early in life? The diathesis hypothesis. *Pediatr. Diabetes* **7,** 289–297

301. Tuzcu, M., and Baydas, G. (2006) Effect of melatonin and vitamin E on diabetes-induced learning and memory impairment in rats. *Eur. J. Pharmacol.* **537,** 106–110

302. Isik, A., Koca, S. S., Ozturk, A., and Mermi, O. (2006) Anxiety and depression in patients with rheumatoid arthritis. *Clin. Rheumatol.* **26,** 872–878

303. Iaboni, A., Ibanez, D., Gladman, D. D., Urowitz, M. B., and Moldofsky, H. (2006) Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. *J. Rheumatol.* **33,** 2453–2457

304. Kozora, E., Ellison, M. C., and West, S. (2006) Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. *Arthritis Rheum.* **55,** 628–635

305. Filipovic, B. R., Filipovic, B. F., Kerkez, M., Milinic, N., and Randelovic, T. (2007) Depression and anxiety levels in therapy-naive patients with inflammatory bowel disease and cancer of the colon. *World J. Gastroenterol.* **13,** 438–443

306. Mikocka-Walus, A. A., Turnbull, D. A., Moulding, N. T., Wilson, I. G., Andrews, J. M., and Holtmann, G. J. (2007) Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: A literature review. *Inflamm. Bowel Dis.* **13,** 225–234

307. Fuller-Thomson, E., and Sulman, J. (2006) Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. *Inflamm. Bowel. Dis.* **12,** 697–707

308. Mackner, L. M., Crandall, W. V., and Szigethy, E. M. (2006) Psychosocial functioning in pediatric inflammatory bowel disease. *Inflamm. Bowel Dis.* **12,** 239–244

309. Herva, A., Laitinen, J., Miettunen, J., Veijola, J., Karvonen, J. T., Laksy, K., and Joukamaa, M. (2006) Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study. *Int. J. Obes. (Lond.)* **30,** 520–527

310. Kress, A. M., Peterson, M. R., and Hartzell, M. C. (2006) Association between obesity and depressive symptoms among U.S. Military active duty service personnel, 2002. *J. Psychosom. Res.* **60,** 263–271

311. Heo, M., Pietrobelli, A., Fontaine, K. R., Sirey, J. A., and Faith, M. S. (2006) Depressive mood and obesity in US adults: comparison and moderation by sex, age, and race. *Int. J. Obes. (Lond.)* **30,** 513–519

312. Brands, A. M., Van den Berg, E., Manschot, S. M., Biessels, G. J., Kappelle, L. J., de Hann, E. H., and Kessels, R. P. (2007) A detailed profile of cognitive dysfunction and its relation to psychological distress in patients with type 2 diabetes mellitus. *J. Int. Neuropsychol. Soc.* **13,** 288–297

313. VandenBerg, E., Kessels, R. P., Kappelle, L. J., de Hann, E. H., and Biessels, G. J. (2006) Type 2 diabetes, cognitive function and dementia: vascular and metabolic determinants. *Drugs Today (Barc.)* **42,** 741–754

314. Halling, A., and Berglund, J. (2006) Association of diagnosis of ischaemic heart disease, diabetes mellitus and heart failure with cognitive function in the elderly population. *Eur. J. Gen. Pract.* **12,** 114–119

315. Yirmiya, R., Goshen, I., Bajayo, A., Kreisel, T., Feldman, S., Tam, J., Trembovler, V., Csernus, V., Shohami, E., and Bab, I. (2006) Depression induces bone loss through stimulation of the sympathetic nervous system. *Proc. Natl. Acad. Sci. U. S. A.* **103,** 16876–16881

316. Gold, D. T., and Solimeo, S. (2006) Osteoporosis and depression: a historical perspective. *Curr. Osteoporos. Rep.* **4,** 134–139

317. Liu, C. Z., Yu, J. C., Cheng, H. Y., Jiang, Z. G., Li, T., Zhang, X. Z., Zhang, L. L., and Han, J. X. (2006) Spatial memory performance and hippocampal neuron number in osteoporotic SAMP6 mice. *Exp. Neurol.* **201,** 452–460

318. Heflin, L. H., Meyerowitz, B. E., Hall, P., Lichtenstein, P., Johansson, B., Pedersen, N. L., and Gatz, M. (2005) Cancer as a risk factor for long-term cognitive deficits and dementia. *J. Natl. Cancer Inst.* **97,** 854–856

319. Jehn, C. F., Kuehnhardt, D., Bartholomae, A., Pfeiffer, S., Krebs, M., Regierer, A. C., Schmid, P., Possinger, K., and Flath, B. C. (2006) Biomarkers of depression in cancer patients. *Cancer* **107,** 2723–2729

320. Gunstad, J., Bausserman, L., Paul, R. H., Tate, D. F., Hoth, K., Poppas, A., Jefferson, A. L., and Cohen, R. A. (2006) C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. *J. Clin. Neurosci.* **13,** 540–546

321. Cruess, D. G., Douglas, S. D., Petitto, J. M., Have, T. T., Gettes, D., Dube, B., Cary, M., and Evans, D. L. (2005) Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. *Am. J. Psychiatry* **162,** 2125–2130

322. VanHoudenhove, B., and Luyten, P. (2006) Stress, depression and fibromyalgia. *Acta Neurol. Belg.* **106,** 149–156

323. Wainwright, P. E., and Colombo, J. (2006) Nutrition and the development of cognitive functions: interpretation of behavioral studies in animals and human infants. *Am. J. Clin. Nutr.* **84,** 961–970

324. Cheatham, C. L., Colombo, J., and Carlson, S. E. (2006) N-3 fatty acids and cognitive and visual acuity development: methodologic and conceptual considerations. *Am. J. Clin. Nutr.* **83,** 1458S–1466S

325. Dardenne, O., Prud'homme, J., Arabian, A., Glorieux, F. H., and St-Arnaud, R. (2001) Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. *Endocrinology* **142,** 3135–3141

326. Panda, D. K., Miao, D., Tremblay, M. L., Sirois, J., Farookhi, R., Hendy, G. N., and Goltzman, D. (2001) Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. *Proc. Natl. Acad. Sci. U. S. A.* **98,** 7498–7503

327. St-Arnaud, R. (1999) Targeted inactivation of vitamin D hydroxylases in mice. *Bone* **25,** 127–129

328. Yee, Y. K., Chintalacharuvu, S. R., Lu, J., and Nagpal, S. (2005) Vitamin D receptor modulators for inflammation and cancer. *Mini Rev. Med. Chem.* **5,** 761–778

329. Mathieu, C., and Adorini, L. (2002) The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. *Trends Mol. Med.* **8,** 174–179

330. Beer, T. M., and Myrthue, A. (2004) Calcitriol in cancer treatment: from the lab to the clinic. *Mol. Cancer Ther.* **3,** 373–381

331. Nagpal, S., Lu, J., and Boehm, M. F. (2001) Vitamin D analogs: mechanism of action and therapeutic applications. *Curr. Med. Chem.* **8,** 1661–1679

332. Adorini, L. (2005) Intervention in autoimmunity: the potential of vitamin D receptor agonists. *Cell. Immunol.* **233,** 115–124

333. Dawson-Hughes, B., Heaney, R. P., Holick, M. F., Lips, P., Meunier, P. J., and Vieth, R. (2005) Estimates of optimal vitamin D status. *Osteoporos. Int.* **16,** 713–716

334. Vieth, R., Bischoff-Ferrari, H., Boucher, B. J., Dawson-Hughes, B., Garland, C. F., Heaney, R. P., Holick, M. F., Hollis, B. W., Lamberg-Allardt, C., McGrath, J. J., Norman, A. W., Scragg, R., Whiting, S. J., Willett, W. C., and Zittermann, A. (2007) The urgent need to recommend an intake of vitamin D that is effective. *Am. J. Clin. Nutr.* **85,** 649–650

335. Bischoff-Ferrari, H., Giovannucci, E., Willett, W., Dietrich, T., and Dawson-Hughes, B. (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am. J. Clin. Nutr.* **84,** 18–28

336. Heaney, R. P. (1999) Lessons for nutritional science from vitamin D. *Am. J. Clin. Nutr.* **69,** 825–826

337. Looker, A. C., Dawson-Hughes, B., Calvo, M. S., Gunter, E. W., and Sahyoun, N. R. (2002) Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. *Bone* **30,** 771–777

338. Hypponen, E., and Power, C. (2007) Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. *Am. J. Clin. Nutr.* **85,** 860–868

339. Elliott, M. E., Binkley, N. C., Carnes, M., Zimmerman, D. R., Petersen, K., Knapp, K., Behlke, J. M., Ahmann, N., and Kieser, M. A. (2003) Fracture risks for women in long-term care: high prevalence of calcaneal osteoporosis and hypovitaminosis D. *Pharmacotherapy* **23,** 702–710

340. Harris, S. S. (2006) Vitamin D and African Americans. *J. Nutr.* **136,** 1126–1129

341. Bodnar, L. M., Simhan, H. N., Powers, R. W., Frank, M. P., Cooperstein, E., and Roberts, J. M. (2007) High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. *J. Nutr.* **137,** 447–452

342. Nesby-O'Dell, S., Scanlon, K. S., Cogswell, M. E., Gillespie, C., Hollis, B. W., Looker, A. C., Allen, C., Doughertly, C., Gunter, E. W., and Bowman, B. A. (2002) Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994. *Am. J. Clin. Nutr.* **76,** 187–192

343. Garland, C. F., Gorham, E. D., Mohr, S. B., Grant, W. B., Giovannucci, E. L., Lipkin, M., Newmark, H., Holick, M. F., and Garland, F. C. (2007) Vitamin D and prevention of breast cancer: pooled analysis. *J. Steroid Biochem. Mol. Biol.* **103,** 708–711